Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 690 articles:
HTML format



Single Articles


    May 2020
  1. SHALASH A, Roushdy T, Essam M, Fathy M, et al
    Mental health, physical activity and quality of life in Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 May 19. doi: 10.1002/mds.28134.
    PubMed    


  2. TURNER TH, Dale ML
    Inconsistent Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28108.
    PubMed    


  3. MILOSEVIC L, Scherer M, Cebi I, Guggenberger R, et al
    Online Mapping with the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28093.
    PubMed     Abstract available


  4. MARRAS C, Pequeno P, Austin PC, Gershon AS, et al
    Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study.
    Mov Disord. 2020 May 15. doi: 10.1002/mds.28085.
    PubMed    


  5. CHRISTINE CW, Auinger P, Saleh N, Tian M, et al
    Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.
    Mov Disord. 2020 May 14. doi: 10.1002/mds.28073.
    PubMed     Abstract available


  6. CRAIG CE, Jenkinson NJ, Brittain JS, Grothe MJ, et al
    Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease.
    Mov Disord. 2020 May 13. doi: 10.1002/mds.28051.
    PubMed     Abstract available


  7. HATTORI N, Mochizuki H, Hasegawa K, Nomoto M, et al
    Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28071.
    PubMed     Abstract available


  8. BOIKA AV
    A postCOVID-19 parkinsonism in the future?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28117.
    PubMed    


  9. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Can the 2019 novel coronavirus cause Parkinson's disease?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28118.
    PubMed    


  10. SALARI M, Zali A, Ashrafi F, Etemadifar M, et al
    Incidence of Anxiety in Parkinson's Disease during Coronavirus disease (COVID-19) pandemic.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28116.
    PubMed    


  11. BOOT E, Mentzel TQ, Palmer LD, van Harten PN, et al
    Age-Related Parkinsonian Signs in Microdeletion 22q11.2.
    Mov Disord. 2020 May 9. doi: 10.1002/mds.28080.
    PubMed     Abstract available


  12. SCHNEIDER SA, Alcalay RN
    Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Mov Disord. 2020 May 7. doi: 10.1002/mds.28072.
    PubMed    


  13. UCHIDA Y, Kan H, Sakurai K, Inui S, et al
    Magnetic Susceptibility Associates with Dopaminergic Deficits and Cognition in Parkinson's Disease.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28077.
    PubMed     Abstract available


  14. FAN SP, Lee NC, Lin CH
    Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28079.
    PubMed     Abstract available


  15. PETERS S, Gallo V, Vineis P, Middleton LT, et al
    Alcohol Consumption and Risk of Parkinson's Disease: Data from a Large Prospective European Cohort.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28039.
    PubMed     Abstract available


  16. HORN MA, Gulberti A, Gulke E, Buhmann C, et al
    A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28083.
    PubMed     Abstract available


  17. HIRSCH EC, Standaert DG
    Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28075.
    PubMed     Abstract available


  18. TAKESHIGE-AMANO H, Saiki S, Fujimaki M, Ueno SI, et al
    Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28068.
    PubMed     Abstract available


  19. ARCHER DB, Mitchell T, Burciu RG, Yang J, et al
    Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28060.
    PubMed     Abstract available


  20. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28052.
    PubMed     Abstract available


  21. BONET-PONCE PHD L, Cookson MR
    Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Mov Disord. 2020;35:721-723.
    PubMed    


  22. KIM HJ, Jeon B
    Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?
    Mov Disord. 2020;35:901-902.
    PubMed    


    April 2020
  23. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28066.
    PubMed     Abstract available


  24. GALOPPIN M, Berroir P, Soucy JP, Suzuki Y, et al
    Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28046.
    PubMed     Abstract available


  25. WILSON H, Pagano G, de Natale ER, Mansur A, et al
    Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28064.
    PubMed     Abstract available


  26. ANTONINI A, Leta V, Teo J, Chaudhuri KR, et al
    Outcome of Parkinson's Disease patients affected by COVID-19.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28104.
    PubMed    


  27. LOPEZ AM, Trujillo P, Hernandez AB, Lin YC, et al
    Structural Correlates of the Sensorimotor Cerebellum in Parkinson's Disease and Essential Tremor.
    Mov Disord. 2020 Apr 28. doi: 10.1002/mds.28044.
    PubMed     Abstract available


  28. WILKE C, Dos Santos MCT, Schulte C, Deuschle C, et al
    Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Mov Disord. 2020 Apr 27. doi: 10.1002/mds.28026.
    PubMed     Abstract available


  29. PRASAD S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, et al
    Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28065.
    PubMed    


  30. PHILLIPPS C, Longato N, Bereau M, Carriere N, et al
    Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28053.
    PubMed    


  31. PRASAD S, Holla VV, Neeraja K, Surisetti BK, et al
    Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers.
    Mov Disord. 2020 Apr 17. doi: 10.1002/mds.28088.
    PubMed    


  32. YOO JE, Jang W, Shin DW, Jeong SM, et al
    Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation-wide Retrospective Cohort Study.
    Mov Disord. 2020 Apr 15. doi: 10.1002/mds.28055.
    PubMed     Abstract available


  33. HOPFNER F, Mueller SH, Szymczak S, Junge O, et al
    Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease.
    Mov Disord. 2020 Apr 8. doi: 10.1002/mds.28037.
    PubMed     Abstract available


  34. OLANOW CW, Standaert DG, Kieburtz K, Viegas T, et al
    Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28027.
    PubMed     Abstract available


  35. PAPA SM, Brundin P, Fung VSC, Kang UJ, et al
    Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28067.
    PubMed    


  36. KARL JA, Ouyang B, Goetz S, Metman LV, et al
    A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study.
    Mov Disord. 2020 Apr 4. doi: 10.1002/mds.28048.
    PubMed     Abstract available


    March 2020
  37. VIEIRA SRL, Toffoli M, Campbell P, Schapira AHV, et al
    Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy.
    Mov Disord. 2020 Mar 27. doi: 10.1002/mds.28030.
    PubMed    


  38. FEARON C, Farrell MA
    Disease-Specific Strains of alpha-Synuclein in Multiple System Atrophy and Parkinson's Disease: But Why?
    Mov Disord. 2020 Mar 23. doi: 10.1002/mds.28035.
    PubMed    


  39. SVENNINGSSON P, Odin P, Dizdar N, Johansson A, et al
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
    Mov Disord. 2020 Mar 21. doi: 10.1002/mds.28020.
    PubMed     Abstract available


  40. DONZUSO G, Agosta F, Canu E, Filippi M, et al
    MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Mov Disord. 2020 Mar 17. doi: 10.1002/mds.28025.
    PubMed     Abstract available


  41. LEODORI G, Belvisi D, De Bartolo MI, Fabbrini A, et al
    Re-emergent Tremor in Parkinson's Disease: The Role of the Motor Cortex.
    Mov Disord. 2020 Mar 16. doi: 10.1002/mds.28022.
    PubMed     Abstract available


  42. HIRATA K, Hattori T, Kina S, Chen Q, et al
    Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Mar 12. doi: 10.1002/mds.28024.
    PubMed     Abstract available


  43. PALERMO G, Giannoni S, Frosini D, Morganti R, et al
    Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28008.
    PubMed     Abstract available


  44. SHIN C, Lim Y, Lim H, Ahn TB, et al
    Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28016.
    PubMed     Abstract available


  45. NUTT JG, Curtze C, Hiller A, Anderson S, et al
    Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
    Mov Disord. 2020 Mar 9. doi: 10.1002/mds.27993.
    PubMed     Abstract available


  46. WIJEYEKOON RS, Moore SF, Farrell K, Breen DP, et al
    Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
    Mov Disord. 2020 Mar 4. doi: 10.1002/mds.28015.
    PubMed     Abstract available


  47. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    Reply to: Comment on "the role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521-522.
    PubMed    


  48. XU Y, He Q, Wang W
    Comment on "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521.
    PubMed    


  49. CASTILLO-TORRES SA, Sanchez-Cardenas M, Soto-Rincon CA, Chavez-Luevanos B, et al
    Kidney dysfunction and risk of Parkinson's disease: The issue of equations and large numbers.
    Mov Disord. 2020;35:519.
    PubMed    


  50. NAM GE, Kim NH, Han K, Choi KM, et al
    Reply to: Kidney Dysfunction and Risk of Parkinson's Disease: The Issue of Equations and Large Number".
    Mov Disord. 2020;35:520.
    PubMed    


  51. HANUSKA J, Rusz J, Bezdicek O, Dusek P, et al
    Comment on "pro-saccades predict cognitive decline in Parkinson's disease: ICICLE-PD".
    Mov Disord. 2020;35:522.
    PubMed    


    February 2020
  52. CHUNG SJ, Kim HR, Jung JH, Lee PH, et al
    Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28012.
    PubMed     Abstract available


  53. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28009.
    PubMed     Abstract available


  54. ELFIL M, Kamel S, Kandil M, Koo BB, et al
    Implications of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28004.
    PubMed     Abstract available


  55. WILLIAMS NM, Hubbard L, Sandor C, Webber C, et al
    Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28001.
    PubMed    


  56. MIRELMAN A, Hillel I, Rochester L, Del Din S, et al
    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28006.
    PubMed     Abstract available


  57. SIMUNI T, Brumm MC, Uribe L, Caspell-Garcia C, et al
    Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989.
    PubMed     Abstract available


  58. SINGLETON AB, Gasser T
    The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Mov Disord. 2020 Feb 17. doi: 10.1002/mds.27999.
    PubMed    


  59. JAFARI Z, Kolb BE, Mohajerani MH
    Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020 Feb 13. doi: 10.1002/mds.28000.
    PubMed     Abstract available


  60. SEO SH, Bacolla A, Yoo D, Koo YJ, et al
    Replication-Based Rearrangements Are a Common Mechanism for SNCA Duplication in Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27998.
    PubMed     Abstract available


  61. LITTLE S, Brown P
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27996.
    PubMed     Abstract available


  62. KNOX MG, Adler CH, Shill HA, Driver-Dunckley E, et al
    Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27991.
    PubMed     Abstract available


  63. POWELL A, Muller AJ, O'Callaghan C, Sourty M, et al
    Dopamine and Functional Connectivity in Patients With Parkinson's Disease and Visual Hallucinations.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27995.
    PubMed    


  64. PINTER D, Janszky J, Kovacs N
    Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study".
    Mov Disord. 2020;35:375.
    PubMed    


  65. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study".
    Mov Disord. 2020;35:376-377.
    PubMed    


  66. FOLTYNIE T, Athauda D
    Diabetes, BMI, and Parkinson's.
    Mov Disord. 2020;35:201-203.
    PubMed    


  67. PALMA JA
    Renal dysfunction might be a marker of cardiovascular dysautonomia in prodromal alpha-synucleinopathies.
    Mov Disord. 2020;35:374.
    PubMed    


    January 2020
  68. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Pierre D. and the first photographs of Parkinson's disease.
    Mov Disord. 2020 Jan 24. doi: 10.1002/mds.27965.
    PubMed    


  69. GANG M, Baba T, Hosokai Y, Nishio Y, et al
    Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Mov Disord. 2020 Jan 23. doi: 10.1002/mds.27988.
    PubMed     Abstract available


  70. BARTH AL, Schneider JS, Johnston TH, Hill MP, et al
    NYX-458 improves cognitive performance in a primate Parkinson's disease model.
    Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27962.
    PubMed     Abstract available


  71. IWAKI H, Blauwendraat C, Makarious MB, Bandres-Ciga S, et al
    Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
    Mov Disord. 2020 Jan 20. doi: 10.1002/mds.27974.
    PubMed     Abstract available


  72. VIJAYAN S, Singh B, Ghosh S, Stell R, et al
    Brainstem ventilatory dysfunction: A plausible mechanism for dyspnea in Parkinson's Disease?
    Mov Disord. 2020 Jan 15. doi: 10.1002/mds.27932.
    PubMed     Abstract available


  73. VACHEZ Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, et al
    Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27953.
    PubMed     Abstract available


  74. SAMPEDRO F, Marin-Lahoz J, Martinez-Horta S, Perez-Gonzalez R, et al
    CLU rs11136000 promotes early cognitive decline in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27949.
    PubMed     Abstract available


  75. WIRTH T, Mariani LL, Bergant G, Baulac M, et al
    Loss-of-function mutations in NR4A2 cause dopa-responsive dystonia Parkinsonism.
    Mov Disord. 2020 Jan 10. doi: 10.1002/mds.27982.
    PubMed     Abstract available


  76. JI S, Wang C, Qiao H, Gu Z, et al
    Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study.
    Mov Disord. 2020 Jan 8. doi: 10.1002/mds.27971.
    PubMed     Abstract available


  77. RANGO M, Dossi G, Squarcina L, Bonifati C, et al
    Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation.
    Mov Disord. 2020 Jan 2. doi: 10.1002/mds.27946.
    PubMed     Abstract available


  78. SANTOS-LOBATO BL, Schumacher-Schuh AF, Tumas V
    Predictors of Motor Complications in Early Parkinson's Disease.
    Mov Disord. 2020;35:191-192.
    PubMed    


  79. BAIG F, Kelly MJ, Lawton MA, Ben-Shlomo Y, et al
    Reply to: "Predictors of motor complications in early Parkinson's disease".
    Mov Disord. 2020;35:193.
    PubMed    


  80. KIM HJ, Mason S, Foltynie T, Winder-Rhodes S, et al
    Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.
    Mov Disord. 2020;35:185-190.
    PubMed     Abstract available


    December 2019
  81. GENOUD S, Senior AM, Hare DJ, Double KL, et al
    Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.
    Mov Disord. 2019 Dec 31. doi: 10.1002/mds.27947.
    PubMed     Abstract available


  82. SCHINDLBECK KA, Lucas-Jimenez O, Tang CC, Morbelli S, et al
    Metabolic network abnormalities in drug-naive Parkinson's Disease.
    Mov Disord. 2019 Dec 24. doi: 10.1002/mds.27960.
    PubMed     Abstract available


  83. WHITE RL 3RD, Campbell MC, Yang D, Shannon W, et al
    Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naive Parkinson's Disease.
    Mov Disord. 2019 Dec 19. doi: 10.1002/mds.27942.
    PubMed     Abstract available


  84. HALL S, Janelidze S, Zetterberg H, Brix B, et al
    Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
    Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950.
    PubMed     Abstract available


  85. WANG Z, Yan J, Wang X, Yuan Y, et al
    Transcranial ultrasound stimulation directly influences the cortical excitability of the motor cortex in Parkinsonian mice.
    Mov Disord. 2019 Dec 12. doi: 10.1002/mds.27952.
    PubMed     Abstract available


  86. CRESSATTI M, Juwara L, Galindez JM, Velly AM, et al
    Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27935.
    PubMed     Abstract available


  87. MONJE MHG, Blesa J, Garcia-Cabezas MA, Obeso JA, et al
    Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27921.
    PubMed     Abstract available


  88. RAVANIDIS S, Bougea A, Papagiannakis N, Maniati M, et al
    Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27928.
    PubMed     Abstract available


  89. COSENTINO C, Baccini M, Putzolu M, Ristori D, et al
    Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-Analyses.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27936.
    PubMed     Abstract available


  90. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Swimming Is Compromised in Parkinson's Disease Patients.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27918.
    PubMed     Abstract available


  91. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion".
    Mov Disord. 2019;34:1932-1933.
    PubMed    


  92. REDDY SP, Socal MP, Rieder CRM, Schumacher-Schuh AF, et al
    Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
    Mov Disord. 2019;34:1929-1930.
    PubMed    


  93. CHAUDHURI KR, Jenner P, Antonini A
    Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
    Mov Disord. 2019;34:1930-1931.
    PubMed    


  94. FINSTERER J
    Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion.
    Mov Disord. 2019;34:1931-1932.
    PubMed    


    November 2019
  95. LOPEZ G, Steward A, Ryan E, Groden C, et al
    Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27916.
    PubMed     Abstract available


  96. JEONG SM, Han K, Kim D, Rhee SY, et al
    Body mass index, diabetes, and the risk of Parkinson's disease.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27922.
    PubMed     Abstract available


  97. MORALES-BRICENO H, Fung VSC
    Enhancement of glycolysis: A potential disease-modifying strategy for Parkinson's disease.
    Mov Disord. 2019 Nov 29. doi: 10.1002/mds.27934.
    PubMed    


  98. DELGADO-ALVARADO M, Marano M, Santurtun A, Urtiaga-Gallano A, et al
    Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27913.
    PubMed     Abstract available


  99. KIM IY, Yang TO, Heath AK, Simpson RF, et al
    Alcohol intake and Parkinson's disease risk in the million women study.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27933.
    PubMed     Abstract available


  100. BETROUNI N, Lopes R, Defebvre L, Leentjens AFG, et al
    Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27931.
    PubMed     Abstract available


  101. MANNE S, Kondru N, Jin H, Anantharam V, et al
    alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27907.
    PubMed     Abstract available


  102. BARBE MT, Tonder L, Krack P, Debu B, et al
    Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications.
    Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
    PubMed     Abstract available


  103. DI CAPRIO V, Modugno N, Mancini C, Olivola E, et al
    Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition.
    Mov Disord. 2019 Nov 21. doi: 10.1002/mds.27920.
    PubMed     Abstract available


  104. BAIANO C, Barone P, Trojano L, Santangelo G, et al
    Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis.
    Mov Disord. 2019 Nov 19. doi: 10.1002/mds.27902.
    PubMed     Abstract available


  105. MERTSALMI TH, Pekkonen E, Scheperjans F
    Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27924.
    PubMed     Abstract available


  106. OOSTERVELD LP, Verberk IMW, Majbour NK, El-Agnaf OM, et al
    CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27897.
    PubMed     Abstract available


  107. PAZ-ALONSO PM, Navalpotro-Gomez I, Boddy P, Dacosta-Aguayo R, et al
    Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27885.
    PubMed     Abstract available


  108. SIDRANSKY E, Arkadir D, Bauer P, Dinur T, et al
    Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27903.
    PubMed    


  109. FANCIULLI A, Goebel G, Lazzeri G, Granata R, et al
    Urinary retention discriminates multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27917.
    PubMed    


  110. GILBERT RM, Standaert DG
    Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27906.
    PubMed    


  111. GAJOS KZ, Reinecke K, Donovan M, Stephen CD, et al
    Computer Mouse Use Captures Ataxia and Parkinsonism, Enabling Accurate Measurement and Detection.
    Mov Disord. 2019 Nov 7. doi: 10.1002/mds.27915.
    PubMed     Abstract available


  112. LAWTON M, Baig F, Toulson G, Morovat A, et al
    Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.
    Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27888.
    PubMed     Abstract available


  113. PETRILLO S, Schirinzi T, Di Lazzaro G, D'Amico J, et al
    Systemic activation of Nrf2 pathway in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27878.
    PubMed     Abstract available


  114. HAQUE ME, Akther M, Jakaria M, Kim IS, et al
    Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27874.
    PubMed     Abstract available


  115. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Reply to: Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1750.
    PubMed    


  116. DE PEDRO-CUESTA J, Martinez-Martin P, Calero M, Almazan-Isla J, et al
    Reconciling etiological views on Parkinson's disease.
    Mov Disord. 2019;34:1750-1752.
    PubMed    


  117. MULROY E, Latorre A, Bhatia KP
    Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1749.
    PubMed    


  118. RUNDEK T, Shpiner DS, Margolesky J
    Perivascular spaces in basal ganglia - An innocent bystander in Parkinson's disease?
    Mov Disord. 2019;34:1585-1587.
    PubMed    


    October 2019
  119. GILAT M, Coeytaux Jackson A, Marshall NS, Hammond D, et al
    Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Randomised Controlled Trial.
    Mov Disord. 2019 Oct 31. doi: 10.1002/mds.27886.
    PubMed     Abstract available


  120. LERCHE S, Wurster I, Roeben B, Zimmermann M, et al
    Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884.
    PubMed     Abstract available


  121. BANDRES-CIGA S, Ahmed S, Sabir MS, Blauwendraat C, et al
    The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.
    Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864.
    PubMed     Abstract available


  122. NOYCE AJ, Bandres-Ciga S, Kim J, Heilbron K, et al
    The Parkinson's Disease Mendelian Randomization Research Portal.
    Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873.
    PubMed     Abstract available


  123. HAYAKAWA H, Nakatani R, Ikenaka K, Aguirre C, et al
    Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology.
    Mov Disord. 2019 Oct 23. doi: 10.1002/mds.27887.
    PubMed     Abstract available


  124. PRETEGIANI E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, et al
    Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861.
    PubMed     Abstract available


  125. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27876.
    PubMed     Abstract available


  126. MORALES-BRICENO H, Mahant N, Ha AD, Chang FCF, et al
    Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27883.
    PubMed    


  127. KOLMANCIC K, Perellon-Alfonso R, Pirtosek Z, Rothwell JC, et al
    Sex differences in Parkinson's disease: A transcranial magnetic stimulation study.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27870.
    PubMed     Abstract available


  128. VAN DER VEEN S, Zutt R, Klein C, Marras C, et al
    Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27828.
    PubMed     Abstract available


  129. SACHELI MA, Neva JL, Lakhani B, Murray DK, et al
    Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865.
    PubMed     Abstract available



  130. Abstracts of the 2019 International Congress of the Parkinson's Disease and Movement Disorders(R).
    Mov Disord. 2019;34 Suppl 2:S1-S930.
    PubMed    


  131. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    Reply to: The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1580-1581.
    PubMed    


  132. PIFL C
    The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1579-1580.
    PubMed    


    September 2019
  133. BOUTHOUR W, Bereau M, Kibleur A, Zacharia A, et al
    Dyskinesia-inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27853.
    PubMed     Abstract available


  134. DAYAL V, Grover T, Tripoliti E, Milabo C, et al
    Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27863.
    PubMed     Abstract available


  135. LEE PC, Artaud F, Cormier-Dequaire F, Rascol O, et al
    Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2019 Sep 13. doi: 10.1002/mds.27854.
    PubMed     Abstract available


  136. IWAKI H, Blauwendraat C, Leonard HL, Kim JJ, et al
    Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27845.
    PubMed     Abstract available


  137. SU TH, Yang HC, Tseng TC, Chou SW, et al
    Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism.
    Mov Disord. 2019 Sep 10. doi: 10.1002/mds.27848.
    PubMed     Abstract available


  138. WONG YC, Luk K, Purtell K, Burke Nanni S, et al
    Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27823.
    PubMed     Abstract available


  139. POTASHKIN J, Huang X, Becker C, Chen H, et al
    Understanding the links between cardiovascular disease and Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27836.
    PubMed     Abstract available


  140. AQUINO CC, Duffley G, Hedges DM, Vorwerk J, et al
    Interleaved deep brain stimulation for dyskinesia management in Parkinson's disease.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27839.
    PubMed     Abstract available


  141. MOHANA SUNDARAM S, Garg P
    The gut-brain axis in Parkinson's disease: A focus on the transport of alpha-Synuclein.
    Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27842.
    PubMed    


  142. FISHMAN P, Lipsman N
    Focused ultrasound as an evolving therapy for Parkinson's disease.
    Mov Disord. 2019;34:1241-1242.
    PubMed    


    August 2019
  143. NISSEN SK, Shrivastava K, Schulte C, Otzen DE, et al
    Alterations in Blood Monocyte Functions in Parkinson's Disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27815.
    PubMed     Abstract available


  144. SILVA DE LIMA AL, Smits T, Darweesh SKL, Valenti G, et al
    Home-based monitoring of falls using wearable sensors in Parkinson's disease.
    Mov Disord. 2019 Aug 26. doi: 10.1002/mds.27830.
    PubMed     Abstract available


  145. TERROBA-CHAMBI C, Bruno V, Millar-Vernetti P, Bruce D, et al
    Design and validation of a new instrument to assess fear of falling in Parkinson's disease.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27820.
    PubMed     Abstract available


  146. GAL O, Polakova K, Hoskovcova M, Tomandl J, et al
    Pavement patterns can be designed to improve gait in Parkinson's disease patients.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27831.
    PubMed     Abstract available


  147. STUART S, Lawson RA, Yarnall AJ, Nell J, et al
    Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD.
    Mov Disord. 2019 Aug 23. doi: 10.1002/mds.27813.
    PubMed     Abstract available


  148. GORGES M, Kuntz B, Del Tredici K, Schmidt DG, et al
    Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27814.
    PubMed     Abstract available


  149. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Parkinsonism and spastic paraplegia type 7: Expanding the spectrum of mitochondrial Parkinsonism.
    Mov Disord. 2019 Aug 21. doi: 10.1002/mds.27812.
    PubMed     Abstract available


  150. FOFFANI G, Trigo-Damas I, Pineda-Pardo JA, Blesa J, et al
    Focused ultrasound in Parkinson's disease: A twofold path toward disease modification.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27805.
    PubMed     Abstract available


  151. HEINZEL S, Berg D, Gasser T, Chen H, et al
    Update of the MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2019 Aug 14. doi: 10.1002/mds.27802.
    PubMed     Abstract available


    July 2019
  152. MOLLENHAUER B, Caspell-Garcia CJ, Coffey CS, Taylor P, et al
    Longitudinal analyses of cerebrospinal fluid alpha-Synuclein in prodromal and early Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27806.
    PubMed     Abstract available


  153. HAQ IU, Snively BM, Sweadner KJ, Suerken CK, et al
    Revising rapid-onset dystonia-parkinsonism: Broadening indications for ATP1A3 testing.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27801.
    PubMed     Abstract available


  154. KARAKATSANI ME, Blesa J, Konofagou EE
    Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease.
    Mov Disord. 2019 Jul 30. doi: 10.1002/mds.27804.
    PubMed     Abstract available


  155. OZTURK M, Abosch A, Francis D, Wu J, et al
    Distinct subthalamic coupling in the ON state describes motor performance in Parkinson's disease.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27800.
    PubMed     Abstract available


  156. AGALLIU I, Ortega RA, Luciano MS, Mirelman A, et al
    Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Mov Disord. 2019 Jul 26. doi: 10.1002/mds.27807.
    PubMed     Abstract available


  157. BOI L, Pisanu A, Greig N, Scerba MT, et al
    Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2019 Jul 23. doi: 10.1002/mds.27799.
    PubMed     Abstract available


  158. TSUKITA K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, et al
    Value of in vivo alpha-synuclein deposits in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27794.
    PubMed     Abstract available


  159. PARK YW, Shin NY, Chung SJ, Kim J, et al
    Magnetic Resonance Imaging-Visible Perivascular Spaces in Basal Ganglia Predict Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2019 Jul 19. doi: 10.1002/mds.27798.
    PubMed     Abstract available


  160. MARAKI MI, Stefanis L, Yannakoulia M, Kosmidis MH, et al
    Motor function and the probability of prodromal Parkinson's disease in older adults.
    Mov Disord. 2019 Jul 17. doi: 10.1002/mds.27792.
    PubMed     Abstract available


  161. PRANGE S, Metereau E, Maillet A, Lhommee E, et al
    Early limbic microstructural alterations in apathy and depression in de novo Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27793.
    PubMed     Abstract available


  162. MOREAU C, Pinto S
    Misconceptions about speech impairment in Parkinson's disease.
    Mov Disord. 2019 Jul 15. doi: 10.1002/mds.27791.
    PubMed    


  163. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27779.
    PubMed     Abstract available


  164. EVERS LJW, Krijthe JH, Meinders MJ, Bloem BR, et al
    Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27790.
    PubMed     Abstract available


  165. OERTEL WH, Henrich MT, Janzen A, Geibl FF, et al
    The locus coeruleus: Another vulnerability target in Parkinson's disease.
    Mov Disord. 2019 Jul 10. doi: 10.1002/mds.27785.
    PubMed    


  166. KELLY MJ, Lawton MA, Baig F, Ruffmann C, et al
    Predictors of motor complications in early Parkinson's disease: A prospective cohort study.
    Mov Disord. 2019 Jul 8. doi: 10.1002/mds.27783.
    PubMed     Abstract available


  167. CARROLL CB, Wyse RKH, Grosset DG
    Statins and Parkinson's: A complex interaction.
    Mov Disord. 2019;34:934-935.
    PubMed    


  168. MORALES-BRICENO H, Fung VSC
    You shall not pass! Gut bacteria can convert levodopa to dopamine.
    Mov Disord. 2019;34:986.
    PubMed    


  169. LATORRE A, Rocchi L, Berardelli A, Bhatia KP, et al
    The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders.
    Mov Disord. 2019;34:936-949.
    PubMed     Abstract available


  170. HINKLE JT, Dawson VL, Dawson TM
    The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.
    Mov Disord. 2019;34:959-969.
    PubMed     Abstract available


  171. KRISMER F, Seppi K, Gobel G, Steiger R, et al
    Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis.
    Mov Disord. 2019;34:1041-1048.
    PubMed     Abstract available


    June 2019
  172. MULLIN S, Beavan M, Bestwick J, McNeill A, et al
    Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27775.
    PubMed     Abstract available


  173. VILA M
    Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease.
    Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27776.
    PubMed     Abstract available


  174. COLLIER TJ, Sortwell CE, Mercado NM, Steece-Collier K, et al
    Cell therapy for Parkinson's disease: Why it doesn't work every time.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27742.
    PubMed     Abstract available


  175. NG ASL, Tan YJ, Zhao Y, Saffari SE, et al
    SNCA Rep1 promoter variability influences cognition in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27768.
    PubMed     Abstract available


  176. FERNANDEZ-SANTIAGO R, Martin-Flores N, Antonelli F, Cerquera C, et al
    SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27770.
    PubMed     Abstract available


  177. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
    Mov Disord. 2019 Jun 24. doi: 10.1002/mds.27777.
    PubMed     Abstract available


  178. WICHMANN T
    Changing views of the pathophysiology of Parkinsonism.
    Mov Disord. 2019 Jun 19. doi: 10.1002/mds.27741.
    PubMed     Abstract available


  179. MATARAZZO M, Arroyo-Gallego T, Montero P, Puertas-Martin V, et al
    Remote Monitoring of Treatment Response in Parkinson's Disease: The Habit of Typing on a Computer.
    Mov Disord. 2019 Jun 18. doi: 10.1002/mds.27772.
    PubMed     Abstract available


  180. BERGSLAND N, Zivadinov R, Schweser F, Hagemeier J, et al
    Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27730.
    PubMed     Abstract available


  181. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Parkinsonism in essential tremor cases: A clinicopathological study.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27729.
    PubMed     Abstract available


  182. DE MICCO R, Esposito F, di Nardo F, Caiazzo G, et al
    Sex-related pattern of intrinsic brain connectivity in drug-naive Parkinson's disease patients.
    Mov Disord. 2019 Jun 10. doi: 10.1002/mds.27725.
    PubMed     Abstract available


  183. PAGANO G, Niccolini F, Wilson H, Yousaf T, et al
    Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.
    Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733.
    PubMed     Abstract available


  184. JABARKHEEL Z, Wagle Shukla A
    Essential requisites for rest tremor assessment in Parkinson's disease.
    Mov Disord. 2019;34:927-929.
    PubMed    


  185. TEIVE HAG, Camargo CHF, Munhoz RP
    Reply to: Early distinction of Parkinson variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019;34:929.
    PubMed    


  186. OBESO JA
    Editor's note: The origin of Parkinson's disease: The importance of environment and lifestyle.
    Mov Disord. 2019;34:799-800.
    PubMed    


  187. FERNAGUT PO
    Dopamine and eating behavior disorders in Parkinson's disease: A complex recipe.
    Mov Disord. 2019;34:767-768.
    PubMed    


  188. OLANOW CW
    Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.
    Mov Disord. 2019;34:812-815.
    PubMed    


    May 2019
  189. HEISS JD, Lungu C, Hammoud DA, Herscovitch P, et al
    Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27724.
    PubMed     Abstract available


  190. PARNETTI L, Bellomo G
    The issue of waste disposal in Parkinson's disease pathogenesis.
    Mov Disord. 2019 May 30. doi: 10.1002/mds.27734.
    PubMed    


  191. EVANS AH, Okai D, Weintraub D, Lim SY, et al
    Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27689.
    PubMed     Abstract available


  192. MILANESE C, Payan-Gomez C, Galvani M, Molano Gonzalez N, et al
    Peripheral mitochondrial function correlates with clinical severity in idiopathic Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27723.
    PubMed     Abstract available


  193. LEWITT PA, Lipsman N, Kordower JH
    Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson's disease.
    Mov Disord. 2019 May 28. doi: 10.1002/mds.27722.
    PubMed     Abstract available


  194. SMYTH N, Skender E, David FJ, Munoz MJ, et al
    Endurance exercise reduces cortisol in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 20. doi: 10.1002/mds.27719.
    PubMed    


  195. MARRAS C, Canning CG, Goldman SM
    Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27720.
    PubMed     Abstract available


  196. UCHIDA Y, Kan H, Sakurai K, Arai N, et al
    Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment.
    Mov Disord. 2019 May 15. doi: 10.1002/mds.27717.
    PubMed     Abstract available


  197. LI Q, Fernagut PO, Bezard E
    l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
    Mov Disord. 2019 May 13. doi: 10.1002/mds.27715.
    PubMed    


  198. THOMASSON N, Pioli E, Friedel C, Monseur A, et al
    Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model.
    Mov Disord. 2019 May 11. doi: 10.1002/mds.27714.
    PubMed    


  199. OBESO JA
    Editor's note: Prodromal Parkinson's disease.
    Mov Disord. 2019;34:664.
    PubMed    


  200. LI J, Dauer W
    Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
    Mov Disord. 2019;34:682.
    PubMed    


    April 2019
  201. NAM GE, Kim NH, Han K, Choi KM, et al
    Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly.
    Mov Disord. 2019 Apr 25. doi: 10.1002/mds.27704.
    PubMed     Abstract available


  202. MINEO D, Cacace F, Mancini M, Vannelli A, et al
    Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
    Mov Disord. 2019 Apr 19. doi: 10.1002/mds.27683.
    PubMed     Abstract available


  203. CHAUDHURI KR, Jenner P, Antonini A
    Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Mov Disord. 2019 Apr 14. doi: 10.1002/mds.27691.
    PubMed    


  204. VAN DER ZEE S, Vallez Garcia D, Elsinga PH, Willemsen ATM, et al
    [(18) F]Fluoroethoxybenzovesamicol in Parkinson's disease patients: Quantification of a novel cholinergic positron emission tomography tracer.
    Mov Disord. 2019 Apr 12. doi: 10.1002/mds.27698.
    PubMed    


  205. CHEN Y, Cen Z, Zheng X, Pan Q, et al
    LRP10 in autosomal-dominant Parkinson's disease.
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27693.
    PubMed     Abstract available


  206. PETERSEN MS, Lophaven SN, Lynge E, Weihe P, et al
    What does migration between the faroe islands and denmark tell us about the etiology of Parkinson's disease?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27692.
    PubMed    


  207. GRAFF S, Petkovic S
    Parkinson's disease: How do highly toxic alpha-Synuclein/PAR aggregates mediate neuronal cell death?
    Mov Disord. 2019 Apr 9. doi: 10.1002/mds.27688.
    PubMed    


  208. BARBAGALLO G, Quattrone A
    Does levodopa have a disease-modifying effect in Parkinson's disease? Evidence from a delayed-start trial.
    Mov Disord. 2019 Apr 8. doi: 10.1002/mds.27686.
    PubMed    


  209. BLAUWENDRAAT C, Heilbron K, Vallerga CL, Bandres-Ciga S, et al
    Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms.
    Mov Disord. 2019 Apr 7. doi: 10.1002/mds.27659.
    PubMed     Abstract available


  210. JEONG SM, Jang W, Shin DW
    Association of statin use with Parkinson's disease: Dose-response relationship.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27681.
    PubMed     Abstract available


  211. LI Y, Wang C, Wang J, Zhou Y, et al
    Mild cognitive impairment in de novo Parkinson's disease: A neuromelanin MRI study in locus coeruleus.
    Mov Disord. 2019 Apr 2. doi: 10.1002/mds.27682.
    PubMed     Abstract available



  212. 32nd ANNUAL SYMPOSIUM ON ETIOLOGY, PATHOGENESIS, AND TREATMENT OF PARKINSON DISEASE AND OTHER MOVEMENT DISORDERS.
    Mov Disord. 2019;34.
    PubMed    


  213. KISHORE A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, et al
    Understanding the role of genetic variability in LRRK2 in Indian population.
    Mov Disord. 2019;34:496-505.
    PubMed     Abstract available


    March 2019
  214. LANG S, Hanganu A, Gan LS, Kibreab M, et al
    Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson's disease.
    Mov Disord. 2019 Mar 29. doi: 10.1002/mds.27674.
    PubMed     Abstract available


  215. POSTUMA RB, Berg D
    Prodromal Parkinson's Disease: The Decade Past, the Decade to Come.
    Mov Disord. 2019 Mar 28. doi: 10.1002/mds.27670.
    PubMed     Abstract available


  216. WEINTRAUB D
    Impulse control disorders in Parkinson's disease: A 20-year odyssey.
    Mov Disord. 2019 Mar 26. doi: 10.1002/mds.27668.
    PubMed    


  217. PRICE RJ, Fisher DG, Suk JS, Hanes J, et al
    Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?
    Mov Disord. 2019 Mar 25. doi: 10.1002/mds.27675.
    PubMed    


  218. ESPAY AJ, Hausdorff JM, Sanchez-Ferro A, Klucken J, et al
    A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27671.
    PubMed     Abstract available


  219. VIZCARRA JA, Sanchez-Ferro A, Maetzler W, Marsili L, et al
    The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age.
    Mov Disord. 2019 Mar 22. doi: 10.1002/mds.27673.
    PubMed    


  220. ARLOTTI M, Palmisano C, Minafra B, Todisco M, et al
    Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient.
    Mov Disord. 2019 Mar 20. doi: 10.1002/mds.27657.
    PubMed    


  221. MORRIS R, Yarnall AJ, Hunter H, Taylor JP, et al
    Noninvasive vagus nerve stimulation to target gait impairment in Parkinson's disease.
    Mov Disord. 2019 Mar 19. doi: 10.1002/mds.27664.
    PubMed    


  222. GUO Y, Xu W, Liu FT, Li JQ, et al
    Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27665.
    PubMed     Abstract available


  223. MONDAL B, Choudhury S, Simon B, Baker MR, et al
    Noninvasive vagus nerve stimulation improves gait and reduces freezing of gait in Parkinson's disease.
    Mov Disord. 2019 Mar 14. doi: 10.1002/mds.27662.
    PubMed    


  224. DE HEMPTINNE C, Wang DD, Miocinovic S, Chen W, et al
    Pallidal thermolesion unleashes gamma oscillations in the motor cortex in Parkinson's disease.
    Mov Disord. 2019 Mar 13. doi: 10.1002/mds.27658.
    PubMed     Abstract available


  225. KANG UJ, Boehme AK, Fairfoul G, Shahnawaz M, et al
    Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.
    Mov Disord. 2019 Mar 6. doi: 10.1002/mds.27646.
    PubMed     Abstract available


  226. MAGHZI H, Hogg EJ, Tan E, Pagano G, et al
    Adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2019;34:442.
    PubMed    


  227. BREEN DP, Halliday GM, Lang AE
    Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end?
    Mov Disord. 2019;34:307-316.
    PubMed     Abstract available


  228. ARENS J, Storzer L, Hirschmann J, Dalal SS, et al
    Freezing of gait does not modulate beta oscillations in mesial cortical motor areas.
    Mov Disord. 2019;34:436.
    PubMed    


    February 2019
  229. FARRER MJ, Follett J
    Endosomal trafficking leads the way in Parkinson's disease.
    Mov Disord. 2019 Feb 27. doi: 10.1002/mds.27647.
    PubMed    


  230. ALCALAY RN, Mallett V, Vanderperre B, Tavassoly O, et al
    SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27642.
    PubMed     Abstract available


  231. LIN CH, Chen PL, Tai CH, Lin HI, et al
    A clinical and genetic study of early-onset and familial parkinsonism in taiwan: An integrated approach combining gene dosage analysis and next-generation sequencing.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27633.
    PubMed     Abstract available


  232. FANCIULLI A, Goebel G, Lazzeri G, Scherfler C, et al
    Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Feb 20. doi: 10.1002/mds.27635.
    PubMed    


  233. IKEDA A, Shimada H, Nishioka K, Takanashi M, et al
    Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.
    Mov Disord. 2019 Feb 17. doi: 10.1002/mds.27623.
    PubMed     Abstract available


  234. QUATTRONE A, Morelli M, Vescio B, Nigro S, et al
    Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27621.
    PubMed     Abstract available


  235. DIEDERICH NJ, James Surmeier D, Uchihara T, Grillner S, et al
    Parkinson's disease: Is it a consequence of human brain evolution?
    Mov Disord. 2019 Feb 13. doi: 10.1002/mds.27628.
    PubMed    


  236. SCHRAG A, Anastasiou Z, Ambler G, Noyce A, et al
    Predicting diagnosis of Parkinson's disease: A risk algorithm based on primary care presentations.
    Mov Disord. 2019 Feb 8. doi: 10.1002/mds.27616.
    PubMed     Abstract available


  237. YSSELSTEIN D, Shulman JM, Krainc D
    Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.
    Mov Disord. 2019 Feb 6. doi: 10.1002/mds.27631.
    PubMed     Abstract available


  238. DAFSARI HS, Martinez-Martin P, Rizos A, Trost M, et al
    EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Mov Disord. 2019 Feb 4. doi: 10.1002/mds.27626.
    PubMed     Abstract available


  239. HENDERSHOTT TR, Zhu D, Llanes S, Zabetian CP, et al
    Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.
    Mov Disord. 2019;34:285-291.
    PubMed     Abstract available


  240. ROSS GW, Abbott RD, Petrovitch H, Duda JE, et al
    Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.
    Mov Disord. 2019;34:228-235.
    PubMed     Abstract available


  241. SEBILLE SB, Rolland AS, Faillot M, Perez-Garcia F, et al
    Normal and pathological neuronal distribution of the human mesencephalic locomotor region.
    Mov Disord. 2019;34:218-227.
    PubMed     Abstract available


    January 2019
  242. HUANG X, Sterling NW, Du G, Sun D, et al
    Brain cholesterol metabolism and Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27609.
    PubMed     Abstract available


  243. ATKINSON-CLEMENT C, Cavazzini E, Zenon A, Witjas T, et al
    Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27625.
    PubMed     Abstract available


  244. BLESA J, Vila M
    Parkinson disease, substantia nigra vulnerability, and calbindin expression: Enlightening the darkness?
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27618.
    PubMed    


  245. BANDRES-CIGA S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, et al
    The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease.
    Mov Disord. 2019 Jan 24. doi: 10.1002/mds.27614.
    PubMed     Abstract available


  246. HOOGLAND J, Boel JA, de Bie RMA, Schmand BA, et al
    Risk of Parkinson's disease dementia related to level I MDS PD-MCI.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27617.
    PubMed     Abstract available


  247. SEPPI K, Ray Chaudhuri K, Coelho M, Fox SH, et al
    Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27602.
    PubMed     Abstract available


  248. WARREN OLANOW C, Torti M, Kieburtz K, Leinonen M, et al
    Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
    Mov Disord. 2019 Jan 17. doi: 10.1002/mds.27610.
    PubMed     Abstract available


  249. MARRAS C, Obeso JA
    We are what we eat - editors' note on the role of diet in Parkinson's disease.
    Mov Disord. 2019;34:1.
    PubMed    


  250. PAUL KC, Chuang YH, Shih IF, Keener A, et al
    The association between lifestyle factors and Parkinson's disease progression and mortality.
    Mov Disord. 2019;34:58-66.
    PubMed     Abstract available


  251. ASCHERIO A, Schwarzschild MA
    Lifestyle and Parkinson's disease progression.
    Mov Disord. 2019;34:7-8.
    PubMed    


  252. GRONICH N, Auriel E, Lavi I, Rennert G, et al
    Reply to: From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:154.
    PubMed    



  253. Retraction: 'Abnormal bone and calcium metabolism in immobilized Parkinson's disease patients,' by Sato Y., Honda Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2019;34:156.
    PubMed    


  254. VOGELNIK K, Kojovic M
    From beta-blockers to Parkinson's disease in respect of essential tremor.
    Mov Disord. 2019;34:153.
    PubMed    


  255. RICCIARDI L, Sorbera C, Barbuto M, Morgante F, et al
    Sleep disturbances are mainly improved by deep brain stimulation of the subthalamic nucleus.
    Mov Disord. 2019;34:154-155.
    PubMed    


  256. HOMAYOON N, Pirpamer L, Franthal S, Katschnig-Winter P, et al
    Nigral iron deposition in common tremor disorders.
    Mov Disord. 2019;34:129-132.
    PubMed     Abstract available


  257. WHITWELL JL, Tosakulwong N, Schwarz CG, Botha H, et al
    MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Mov Disord. 2019;34:105-113.
    PubMed     Abstract available


  258. HARRIS M, Steele J, Williams R, Pinkston J, et al
    MRI-guided laser interstitial thermal thalamotomy for medically intractable tremor disorders.
    Mov Disord. 2019;34:124-129.
    PubMed     Abstract available


  259. FISCHER DL, Sortwell CE
    BDNF provides many routes toward STN DBS-mediated disease modification.
    Mov Disord. 2019;34:22-34.
    PubMed     Abstract available


  260. HARMSEN IE, Lee DJ, Dallapiazza RF, De Vloo P, et al
    Ultra-high-frequency deep brain stimulation at 10,000 Hz improves motor function.
    Mov Disord. 2019;34:146-148.
    PubMed    


    December 2018
  261. LANGLEY J, He N, Huddleston DE, Chen S, et al
    Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27608.
    PubMed     Abstract available


  262. BONANNI L
    The democratic aspect of machine learning: Limitations and opportunities for Parkinson's disease.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27600.
    PubMed    


  263. KIM JJ, Bandres-Ciga S
    The appendix and the risk of Parkinson's disease: Appended notes on correlation and causation.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27599.
    PubMed    


  264. ATASHRAZM F, Hammond D, Perera G, Bolliger MF, et al
    LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27601.
    PubMed     Abstract available


  265. MORGANTE F, Valente EM
    LRP10: A novel disease gene bridging Parkinson's disease and dementia with Lewy body.
    Mov Disord. 2018 Dec 30. doi: 10.1002/mds.27593.
    PubMed    


  266. MARTINEZ-MARTIN P, Macaulay D, Jalundhwala YJ, Mu F, et al
    The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.
    Mov Disord. 2018 Dec 27. doi: 10.1002/mds.27579.
    PubMed     Abstract available


  267. BARICHELLA M, Severgnini M, Cilia R, Cassani E, et al
    Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27581.
    PubMed     Abstract available


  268. JOHNSTON TH, Geva M, Steiner L, Orbach A, et al
    Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Mov Disord. 2018 Dec 21. doi: 10.1002/mds.27565.
    PubMed     Abstract available


  269. STARHOF C, Hejl AM, Heegaard NHH, Carlsen AL, et al
    The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
    Mov Disord. 2018 Dec 17. doi: 10.1002/mds.27542.
    PubMed     Abstract available


  270. CHUNG SJ, Jeon S, Yoo HS, Yoon JH, et al
    Gastrectomy and nigrostriatal dopaminergic depletion in de novo Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27580.
    PubMed    


  271. TRINH J, Lohmann K, Baumann H, Balck A, et al
    Utility and implications of exome sequencing in early-onset Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27559.
    PubMed     Abstract available


  272. BEJR-KASEM H, Pagonabarraga J, Martinez-Horta S, Sampedro F, et al
    Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27557.
    PubMed     Abstract available


  273. ASSAF F, Schiller Y
    A chemogenetic approach for treating experimental Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27554.
    PubMed     Abstract available


  274. GARGOURI F, Gallea C, Mongin M, Pyatigorskaya N, et al
    Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease.
    Mov Disord. 2018 Dec 10. doi: 10.1002/mds.27561.
    PubMed     Abstract available


    November 2018
  275. CUI SS, Du JJ, Liu SH, Meng J, et al
    Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: A pilot multicenter study.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27569.
    PubMed     Abstract available


  276. IRMEN F, Horn A, Meder D, Neumann WJ, et al
    Sensorimotor subthalamic stimulation restores risk-reward trade-off in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27576.
    PubMed     Abstract available


  277. JANKOVIC J
    Pathogenesis-targeted therapeutic strategies in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27534.
    PubMed    


  278. KRISTIANSEN M, Maple-Grodem J, Alves G, Arepalli S, et al
    A paradoxical relationship between family history, onset age, and genetic risk in Parkinson's disease.
    Mov Disord. 2018 Nov 28. doi: 10.1002/mds.27555.
    PubMed    


  279. MOLLENHAUER B, Zimmermann J, Sixel-Doring F, Focke NK, et al
    Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mov Disord. 2018 Nov 23. doi: 10.1002/mds.27492.
    PubMed     Abstract available


  280. SANJARI MOGHADDAM H, Aarabi MH
    Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27509.
    PubMed    


  281. DARVISH H, Bravo P, Tafakhori A, Azcona LJ, et al
    Identification of a large homozygous VPS13C deletion in a patient with early-onset Parkinsonism.
    Mov Disord. 2018 Nov 19. doi: 10.1002/mds.27516.
    PubMed    


  282. CORMIER-DEQUAIRE F, Bekadar S, Anheim M, Lebbah S, et al
    Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.
    Mov Disord. 2018 Nov 16. doi: 10.1002/mds.27519.
    PubMed     Abstract available


  283. LOFREDI R, Neumann WJ, Brucke C, Huebl J, et al
    Pallidal beta bursts in Parkinson's disease and dystonia.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27524.
    PubMed     Abstract available


  284. LYNCH WB, Tschumi CW, Sharpe AL, Branch SY, et al
    Progressively Disrupted Somatodendritic Morphology in Dopamine Neurons in a Mouse Parkinson's Model.
    Mov Disord. 2018 Nov 15. doi: 10.1002/mds.27541.
    PubMed     Abstract available


  285. MOHAMED IBRAHIM N, Ramli R, Koya Kutty S, Shah SA, et al
    Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
    Mov Disord. 2018 Nov 14. doi: 10.1002/mds.27526.
    PubMed    


  286. PICILLO M, Lizarraga KJ, Friesen EL, Chau H, et al
    Parkinsonism due to A53E alpha-synuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27506.
    PubMed     Abstract available


  287. FRIEDERICH A, Flinspach A, Suenkel U, Eschweiler GW, et al
    Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27539.
    PubMed    


  288. DELGADO-ALVARADO M, Dacosta-Aguayo R, Navalpotro-Gomez I, Gago B, et al
    Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27518.
    PubMed     Abstract available


  289. PUTZOLU M, Pelosin E, Ogliastro C, Lagravinese G, et al
    Anodal tDCS over prefrontal cortex improves dual-task walking in Parkinsonian patients with freezing.
    Mov Disord. 2018 Nov 13. doi: 10.1002/mds.27533.
    PubMed    


  290. KUIPERS DJS, Carr J, Bardien S, Thomas P, et al
    PTRHD1 Loss-of-function mutation in an african family with juvenile-onset Parkinsonism and intellectual disability.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27501.
    PubMed     Abstract available


  291. POSTUMA RB
    Mediterranean diets and prodromal Parkinson's disease: A causal line, or a confound circle?
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27538.
    PubMed    


  292. ALBIN RL, Surmeier DJ, Tubert C, Sarter M, et al
    Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.
    Mov Disord. 2018 Nov 6. doi: 10.1002/mds.27540.
    PubMed    


  293. TANGNEY CC
    Diet to beat the odds of prodromal Parkinson's disease?
    Mov Disord. 2018 Nov 5. doi: 10.1002/mds.27520.
    PubMed    


  294. ESPAY AJ, Guskey MT, Norton JC, Coate B, et al
    Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
    Mov Disord. 2018 Nov 2. doi: 10.1002/mds.27488.
    PubMed     Abstract available


  295. OLANOW CW, Kenney C, Bandak S, Kieburtz KD, et al
    Adverse event reporting in clinical trials in Parkinson's Disease: Time for change.
    Mov Disord. 2018 Nov 1. doi: 10.1002/mds.27497.
    PubMed    


  296. SAMOTUS O, Jog M
    Reply to: Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1829-1830.
    PubMed    


  297. MEADOWS SM, Conti MM, Gross L, Chambers NE, et al
    Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Mov Disord. 2018;33:1740-1749.
    PubMed     Abstract available


  298. DE SOUZA CP, Dos Santos MGG, Hamani C, Fonoff ET, et al
    Spinal cord stimulation for gait dysfunction in Parkinson's disease: Essential questions to discuss.
    Mov Disord. 2018;33:1828-1829.
    PubMed    


    October 2018
  299. SACHELI MA, Murray DK, Vafai N, Cherkasova MV, et al
    Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study.
    Mov Disord. 2018 Oct 30. doi: 10.1002/mds.27498.
    PubMed     Abstract available


  300. TRINH J, Zeldenrust FMJ, Huang J, Kasten M, et al
    Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review.
    Mov Disord. 2018 Oct 24. doi: 10.1002/mds.27527.
    PubMed     Abstract available


  301. HABETS JGV, Heijmans M, Kuijf ML, Janssen MLF, et al
    An update on adaptive deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Oct 24. doi: 10.1002.
    PubMed     Abstract available


  302. BETROUNI N, Delval A, Chaton L, Defebvre L, et al
    Electroencephalography-based machine learning for cognitive profiling in Parkinson's disease: Preliminary results.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27528.
    PubMed     Abstract available


  303. HUANG X, Ng SY, Chia NS, Acharyya S, et al
    Higher serum triglyceride levels are associated with Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Oct 21. doi: 10.1002/mds.27521.
    PubMed    


  304. WEERSINK JB, Eikelboom C, Dominguez Vega ZT, Maurits NM, et al
    Forward arm extension as a cue for gait initiation in Parkinson's patients.
    Mov Disord. 2018 Oct 17. doi: 10.1002/mds.27510.
    PubMed    


  305. TOSSERAMS A, Araujo R, Pringsheim T, Post B, et al
    Underrepresentation of women in Parkinson's disease trials.
    Mov Disord. 2018 Oct 11. doi: 10.1002/mds.27505.
    PubMed    


  306. MARAKI MI, Yannakoulia M, Stamelou M, Stefanis L, et al
    Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27489.
    PubMed     Abstract available


  307. VIRMANI T, Pillai L, Glover A, Doerhoff SM, et al
    Impaired step-length setting prior to turning in Parkinson's disease patients with freezing of gait.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27499.
    PubMed    


  308. FABER I, Martinez ARM, Martins CR Jr, Maia ML, et al
    SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27491.
    PubMed     Abstract available


  309. HOLDEN SK, Medina LD, Hoyt B, Sillau SH, et al
    Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.
    Mov Disord. 2018 Oct 10. doi: 10.1002/mds.27487.
    PubMed     Abstract available


  310. BLAUWENDRAAT C, Bras JM, Nalls MA, Lewis PA, et al
    Coding variation in GBA explains the majority of the SYT11-GBA Parkinson's disease GWAS locus.
    Mov Disord. 2018 Oct 9. doi: 10.1002.
    PubMed    


  311. WALDTHALER J, Tsitsi P, Seimyr GO, Benfatto MN, et al
    Eye movements during reading in parkinson's disease: A pilot study.
    Mov Disord. 2018 Oct 8. doi: 10.1002.
    PubMed    


  312. SMITH AM, Depp C, Ryan BJ, Johnston GI, et al
    Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells.
    Mov Disord. 2018 Oct 7. doi: 10.1002.
    PubMed     Abstract available


  313. THALER A, Kozlovski T, Gurevich T, Bar-Shira A, et al
    Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27490.
    PubMed     Abstract available


  314. GREENAMYRE JT
    What's wrong with mitochondria in Parkinson's disease?
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed    


  315. VAN DER VELDEN RMJ, Mulders AEP, Drukker M, Kuijf ML, et al
    Network analysis of symptoms in a Parkinson patient using experience sampling data: An n = 1 study.
    Mov Disord. 2018 Oct 4. doi: 10.1002.
    PubMed     Abstract available


  316. KOROS C, Simitsi A, Prentakis A, Beratis I, et al
    123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451.
    PubMed     Abstract available


  317. BEACH TG, Adler CH
    Importance of low diagnostic Accuracy for early Parkinson's disease.
    Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27485.
    PubMed    


  318. BURCIU RG, Vaillancourt DE
    Imaging of Motor Cortex Physiology in Parkinson's Disease.
    Mov Disord. 2018 Oct 2. doi: 10.1002.
    PubMed     Abstract available



  319. Abstracts of the 2018 International Congress of Parkinson's Disease and Movement Disorders((R)).
    Mov Disord. 2018;33 Suppl 2:S1-S929.
    PubMed    


  320. DULOVIC M, Vos M
    Sleep dysfunction in Parkinson's disease: Novel molecular mechanism and implications for therapy.
    Mov Disord. 2018;33:1558-1559.
    PubMed    


  321. SCHRAG A
    Testing the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018;33:1518-1520.
    PubMed    


  322. WAGLE SHUKLA A, Fox SH
    Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.
    Mov Disord. 2018;33:1560.
    PubMed    


    September 2018
  323. BARTHEL C, van Helvert M, Haan R, Janssen AM, et al
    Visual cueing using laser shoes reduces freezing of gait in parkinson's patients at home.
    Mov Disord. 2018 Sep 29. doi: 10.1002/mds.27455.
    PubMed    


  324. RAMIG L, Halpern A, Spielman J, Fox C, et al
    Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27460.
    PubMed     Abstract available


  325. SICILIANO M, Trojano L, Santangelo G, De Micco R, et al
    Fatigue in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2018 Sep 28. doi: 10.1002/mds.27461.
    PubMed     Abstract available


  326. FABBRI M, Ferreira JJ, Lees A, Stocchi F, et al
    Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Mov Disord. 2018 Sep 27. doi: 10.1002/mds.27475.
    PubMed     Abstract available


  327. VAN DER VELDEN RMJ, Broen MPG, Kuijf ML, Leentjens AFG, et al
    Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review.
    Mov Disord. 2018 Sep 17. doi: 10.1002/mds.27465.
    PubMed     Abstract available


  328. LOHLE M, Mangone G, Wolz M, Beuthien-Baumann B, et al
    Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27466.
    PubMed     Abstract available


  329. LUBOMSKI M, Hayes M, Kennerson M, Ellis M, et al
    A novel Parkinson's disease risk variant, p. W378R, in the Gaucher's disease GBA gene.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed    


  330. HOOGLAND J, van Wanrooij LL, Boel JA, Goldman JG, et al
    Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Abstract available


  331. MESTRE TA
    Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed    


  332. CHARVIN D, Di Paolo T, Bezard E, Gregoire L, et al
    An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
    Mov Disord. 2018 Sep 14. doi: 10.1002/mds.27462.
    PubMed     Abstract available


  333. PALACIOS N, Hughes KC, Cereda E, Schwarzschild MA, et al
    Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women.
    Mov Disord. 2018 Sep 14. doi: 10.1002.
    PubMed     Abstract available


  334. YORITAKA A, Ohtsuka C, Maeda T, Hirayama M, et al
    Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27472.
    PubMed    


  335. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Risk of drowning in people with Parkinson's disease.
    Mov Disord. 2018 Sep 12. doi: 10.1002/mds.27473.
    PubMed    


  336. PCHELINA S, Baydakova G, Nikolaev M, Senkevich K, et al
    Blood lysosphingolipids accumulation in patients with parkinson's disease with glucocerebrosidase 1 mutations.
    Mov Disord. 2018 Sep 7. doi: 10.1002/mds.27393.
    PubMed     Abstract available


  337. GAARE JJ, Nido GS, Sztromwasser P, Knappskog PM, et al
    Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease.
    Mov Disord. 2018 Sep 5. doi: 10.1002.
    PubMed     Abstract available


  338. GUO L, Normando EM, Shah PA, De Groef L, et al
    Oculo-visual abnormalities in Parkinson's disease: Possible value as biomarkers.
    Mov Disord. 2018;33:1390-1406.
    PubMed     Abstract available


  339. VAILLANCOURT DE, Lehericy S
    Illuminating basal ganglia and beyond in Parkinson's disease.
    Mov Disord. 2018;33:1373-1375.
    PubMed    


  340. GRONICH N, Abernethy DR, Auriel E, Lavi I, et al
    beta2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.
    Mov Disord. 2018;33:1465-1471.
    PubMed     Abstract available


    August 2018
  341. INOUE KI, Miyachi S, Nishi K, Okado H, et al
    Recruitment of calbindin into nigral dopamine neurons protects against MPTP-Induced parkinsonism.
    Mov Disord. 2018 Aug 30. doi: 10.1002.
    PubMed     Abstract available


  342. BERG D, Adler CH, Bloem BR, Chan P, et al
    Movement disorder society criteria for clinically established early Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27431.
    PubMed     Abstract available


  343. ROZANI V, Gurevich T, Giladi N, El-Ad B, et al
    Higher serum cholesterol and decreased Parkinson's disease risk: A statin-free cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27413.
    PubMed     Abstract available


  344. MESTRE TA, Shamy M, Benedetti F, Lang AE, et al
    Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27409.
    PubMed     Abstract available


  345. SIEURIN J, Andel R, Tillander A, Valdes EG, et al
    Occupational stress and risk for Parkinson's disease: A nationwide cohort study.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27439.
    PubMed     Abstract available


  346. DEFFAINS M, Iskhakova L, Katabi S, Israel Z, et al
    Longer beta oscillatory episodes reliably identify pathological subthalamic activity in Parkinsonism.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27418.
    PubMed     Abstract available


  347. WANNEVEICH M, Moisan F, Jacqmin-Gadda H, Elbaz A, et al
    Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27447.
    PubMed     Abstract available


  348. POSTUMA RB, Poewe W, Litvan I, Lewis S, et al
    Validation of the MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2018 Aug 25. doi: 10.1002/mds.27362.
    PubMed     Abstract available


  349. LERCHE S, Liepelt-Scarfone I, Wurster I, Schulte C, et al
    Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease.
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27427.
    PubMed     Abstract available


  350. WITEK N, Stebbins GT, Goetz CG
    What influences placebo and nocebo responses in Parkinson's disease?
    Mov Disord. 2018 Aug 22. doi: 10.1002/mds.27416.
    PubMed     Abstract available


  351. PHILLIPS MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, et al
    Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.
    Mov Disord. 2018 Aug 11. doi: 10.1002/mds.27390.
    PubMed     Abstract available


  352. MESTRE TA, Ferreira JJ
    The placebo response in Parkinson's disease and other movement disorders.
    Mov Disord. 2018;33:1193-1194.
    PubMed    


  353. SKORVANEK M, Gelpi E, Mechirova E, Ladomirjakova Z, et al
    alpha-Synuclein antibody 5G4 identifies manifest and prodromal Parkinson's disease in colonic mucosa.
    Mov Disord. 2018;33:1366-1368.
    PubMed    


  354. FERREIRA JJ, Trenkwalder C, Mestre TA
    Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
    Mov Disord. 2018;33:1228-1235.
    PubMed     Abstract available


  355. QUATTRONE A, Barbagallo G, Cerasa A, Stoessl AJ, et al
    Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.
    Mov Disord. 2018;33:1213-1227.
    PubMed     Abstract available


    July 2018
  356. PITCHER TL, Myall DJ, Pearson JF, Lacey CJ, et al
    Parkinson's disease across ethnicities: A nationwide study in New Zealand.
    Mov Disord. 2018 Jul 23. doi: 10.1002/mds.27389.
    PubMed     Abstract available


  357. GUPTA DK, Fahn S, Tatsuoka C, Kang UJ, et al
    Hoehn and Yahr stage 3 and postural stability item in the movement disorder society-unified Parkinson's disease rating scale.
    Mov Disord. 2018;33:1188-1189.
    PubMed    


  358. LOESCH DZ, Tassone F, Mellick GD, Horne M, et al
    Evidence for the role of FMR1 gray zone alleles as a risk factor for parkinsonism in females.
    Mov Disord. 2018;33:1178-1181.
    PubMed     Abstract available


  359. REYES CJ, Westenberger A
    An integrated OMICS approach unravels the elusive genetic cause of X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1095.
    PubMed    


  360. SANTENS P, De Letter M, Lees AJ, Krack P, et al
    Crime and Parkinson's: The jury is out.
    Mov Disord. 2018;33:1092-1094.
    PubMed    


  361. SKORVANEK M, Martinez-Martin P, Stebbins GT, Goetz CG, et al
    Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Mov Disord. 2018;33:1189-1190.
    PubMed    


  362. RAKOVIC A, Domingo A, Grutz K, Kulikovskaja L, et al
    Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism.
    Mov Disord. 2018;33:1108-1118.
    PubMed     Abstract available


  363. EHGOETZ MARTENS KA, Shine JM, Walton CC, Georgiades MJ, et al
    Evidence for subtypes of freezing of gait in Parkinson's disease.
    Mov Disord. 2018;33:1174-1178.
    PubMed     Abstract available


    June 2018

  364. Abstracts of the 2nd Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2018;33.
    PubMed    


    May 2018
  365. SOMMERAUER M, Hansen AK, Parbo P, Fedorova TD, et al
    Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients.
    Mov Disord. 2018 May 24. doi: 10.1002/mds.27411.
    PubMed     Abstract available


  366. CHARLES KA, Naudet F, Bouali-Benazzouz R, Landry M, et al
    Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease.
    Mov Disord. 2018 May 18. doi: 10.1002/mds.27377.
    PubMed     Abstract available


  367. LI J, Ruskey JA, Arnulf I, Dauvilliers Y, et al
    Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27385.
    PubMed     Abstract available


  368. DU G, Lewis MM, Sica C, He L, et al
    Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27318.
    PubMed     Abstract available


  369. TANIGUCHI D, Hatano T, Kamagata K, Okuzumi A, et al
    Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27365.
    PubMed     Abstract available


  370. HELDMANN M, Heeren J, Klein C, Rauch L, et al
    Neuroimaging abnormalities in individuals exhibiting Parkinson's disease risk markers.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27313.
    PubMed     Abstract available


  371. MEROLA A, Romagnolo A, Lopiano L, Espay AJ, et al
    Reply to: "Autonomic dysfunction in Parkinson's disease: The hidden game changer?"
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27421.
    PubMed    


  372. DE PABLO-FERNANDEZ E, Warner TT
    Autonomic dysfunction in Parkinson's disease: The hidden game changer?
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27422.
    PubMed    


  373. BAUFRETON J, Milekovic T, Li Q, McGuire S, et al
    Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27404.
    PubMed     Abstract available


  374. LEWIS MM, Du G, Baccon J, Snyder AM, et al
    Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Mov Disord. 2018 May 14. doi: 10.1002/mds.27381.
    PubMed     Abstract available


  375. ORTUNO-LIZARAN I, Beach TG, Serrano GE, Walker DG, et al
    Phosphorylated alpha-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.
    Mov Disord. 2018 May 8. doi: 10.1002/mds.27392.
    PubMed     Abstract available


  376. LEWITT PA
    Comment on 'Distinct metabolomic signature in cerebrospinal fluid in early Parkinson's disease' by Hiller et al.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27379.
    PubMed    


  377. CEDARBAUM JM
    Elephants, Parkinson's disease, and proof-of-concept clinical trials.
    Mov Disord. 2018 May 3. doi: 10.1002/mds.27398.
    PubMed    


  378. TREZZI JP, Hiller K, Mollenhauer B
    The importance of an independent validation cohort for metabolomics biomarker studies.
    Mov Disord. 2018;33:856.
    PubMed    


    April 2018
  379. LIPSMEIER F, Taylor KI, Kilchenmann T, Wolf D, et al
    Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27376.
    PubMed     Abstract available


  380. SARDI SP, Cedarbaum JM, Brundin P
    Targeted therapies for Parkinson's disease: From genetics to the clinic.
    Mov Disord. 2018 Apr 27. doi: 10.1002/mds.27414.
    PubMed     Abstract available


  381. HANGANU A, Houde JC, Fonov VS, Degroot C, et al
    White matter degeneration profile in the cognitive cortico-subcortical tracts in Parkinson's disease.
    Mov Disord. 2018 Apr 23. doi: 10.1002/mds.27364.
    PubMed     Abstract available


  382. LEFAIVRE SC, Brown MJN, Almeida QJ
    Does cerebellar overactivity contribute to gait and balance deficits in Parkinson's disease?
    Mov Disord. 2018 Apr 20. doi: 10.1002/mds.27396.
    PubMed    


  383. MESTRE TA, Pont-Sunyer C, Kausar F, Visanji NP, et al
    Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
    Mov Disord. 2018 Apr 17. doi: 10.1002/mds.27272.
    PubMed     Abstract available


  384. CONTARINO MF, Marinus J, van Hilten JJ
    Does deep brain stimulation of the subthalamic nucleus prolong survival in Parkinson's Disease?
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27384.
    PubMed    


  385. FRIEDMAN JH
    Quetiapine for Parkinson's Disease psychosis: Evidence-based medicine versus expert belief: A case study.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27378.
    PubMed    


  386. LANG AE, Espay AJ
    Disease modification in Parkinson's Disease: Current approaches, challenges, and future considerations.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27360.
    PubMed     Abstract available


  387. KASTEN M, Hartmann C, Hampf J, Schaake S, et al
    Genotype-phenotype relations for the Parkinson's Disease genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27352.
    PubMed     Abstract available


  388. AMANAT M, Salehi M
    Glitazone in Parkinson's Disease.
    Mov Disord. 2018 Apr 11. doi: 10.1002/mds.27397.
    PubMed    


  389. SCOTT KM, Williams-Gray CH
    Targeting aged astrocytes may be a new therapeutic strategy in Parkinson's disease.
    Mov Disord. 2018 Apr 6. doi: 10.1002/mds.27387.
    PubMed    


    March 2018
  390. MACEROLLO A, Brown MJN
    Beta oscillations and indirect pathway spiny projecting neurons: A selective neuronal mechanism linked to Parkinsonian pathophysiology?
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27388.
    PubMed    


  391. WEIR S, Samnaliev M, Kuo TC, Tierney TS, et al
    Short- and long-term cost and utilization of health care resources in Parkinson's disease in the UK.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27302.
    PubMed     Abstract available


  392. KORDOWER JH, Burke RE
    Disease modification for Parkinson's disease: Axonal regeneration and trophic factors.
    Mov Disord. 2018 Mar 30. doi: 10.1002/mds.27383.
    PubMed     Abstract available


  393. COSSU G, Melis M, Sarchioto M, Melis M, et al
    6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27391.
    PubMed     Abstract available


  394. LITVAN I, Kieburtz K, Troster AI, Aarsland D, et al
    Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27345.
    PubMed     Abstract available


  395. KADHIM S, Pringsheim T, Le A, Fiest KM, et al
    Validating screening tools for depression in Parkinson's disease.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27371.
    PubMed    


  396. MOGHADDAM HS, Arabi MH
    Synaptotagmin-11 Is a novel hotspot in the pathogenesis of parkin-linked Parkinson's disease: New implications for clinical targeting.
    Mov Disord. 2018 Mar 24. doi: 10.1002/mds.27369.
    PubMed    


  397. HOUSER MC, Chang J, Factor SA, Molho ES, et al
    Stool immune profiles evince gastrointestinal inflammation in Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27326.
    PubMed     Abstract available


  398. SIMUNI T, Siderowf A, Lasch S, Coffey CS, et al
    Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27361.
    PubMed     Abstract available


  399. FOX SH, Katzenschlager R, Lim SY, Barton B, et al
    International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27372.
    PubMed     Abstract available


  400. FASANO A, De Vloo P, Llinas M, Hlasny E, et al
    Magnetic resonance imaging-guided focused ultrasound thalamotomy in Parkinson tremor: Reoperation after benefit decay.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27348.
    PubMed    


  401. ANTONINI A, Moro E, Godeiro C, Reichmann H, et al
    Medical and surgical management of advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27340.
    PubMed     Abstract available


  402. FERNANDEZ HH, Boyd JT, Fung VSC, Lew MF, et al
    Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27338.
    PubMed     Abstract available


  403. HEINZEL S, Kasten M, Behnke S, Vollstedt EJ, et al
    Age- and sex-related heterogeneity in prodromal Parkinson's disease.
    Mov Disord. 2018 Mar 23. doi: 10.1002/mds.27349.
    PubMed    


  404. WEINTRAUB D, Troster AI, Marras C, Stebbins G, et al
    Initial cognitive changes in Parkinson's disease.
    Mov Disord. 2018 Mar 15. doi: 10.1002/mds.27330.
    PubMed     Abstract available


  405. CARDOSO F
    Vitamin B12 and Parkinson's disease: What is the relationship?
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27366.
    PubMed    


  406. BECK G, Maehara S, Chang PL, Papa SM, et al
    A selective phosphodiesterase 10A inhibitor reduces l-dopa-induced dyskinesias in parkinsonian monkeys.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27341.
    PubMed     Abstract available


  407. CHRISTINE CW, Auinger P, Joslin A, Yelpaala Y, et al
    Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson's disease.
    Mov Disord. 2018 Mar 6. doi: 10.1002/mds.27301.
    PubMed     Abstract available


  408. PALMA JA, Kaufmann H
    Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.
    Mov Disord. 2018;33:372-390.
    PubMed     Abstract available


  409. CHEN X, Scholz SW
    Identification of new alpha-synuclein regulator by nontraditional drug development pipeline.
    Mov Disord. 2018;33:402.
    PubMed    


    February 2018
  410. SONG W, Kothari V, Velly AM, Cressatti M, et al
    Evaluation of salivary heme oxygenase-1 as a potential biomarker of early Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27328.
    PubMed     Abstract available


  411. GOLDMAN JG, Holden SK, Litvan I, McKeith I, et al
    Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27323.
    PubMed     Abstract available


  412. MORALES-BRICENO H, Sanchez-Hernandez BE, Meyer E, Kurian MA, et al
    Beta-propeller-associated neurodegeneration can present with dominant or isolated parkinsonism.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27294.
    PubMed    


  413. CENCI MA, Crossman AR
    Animal models of l-dopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2018 Feb 28. doi: 10.1002/mds.27337.
    PubMed     Abstract available


  414. MENG Y, Voisin MR, Suppiah S, Kalia SK, et al
    Is there a role for MR-guided focused ultrasound in Parkinson's disease?
    Mov Disord. 2018 Feb 24. doi: 10.1002/mds.27308.
    PubMed    


  415. WEIL RS, Schwarzkopf DS, Bahrami B, Fleming SM, et al
    Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27311.
    PubMed     Abstract available


  416. PERAN P, Barbagallo G, Nemmi F, Sierra M, et al
    MRI supervised and unsupervised classification of Parkinson's disease and multiple system atrophy.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307.
    PubMed     Abstract available


  417. ARGAUD S, Verin M, Sauleau P, Grandjean D, et al
    Facial emotion recognition in Parkinson's disease: A review and new hypotheses.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27305.
    PubMed     Abstract available


  418. FERNANDEZ-SANTIAGO R, Garrido A, Infante J, Gonzalez-Aramburu I, et al
    alpha-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain.
    Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27295.
    PubMed     Abstract available


  419. DAFSARI HS, Silverdale M, Strack M, Rizos A, et al
    Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2018 Feb 21. doi: 10.1002/mds.27283.
    PubMed     Abstract available


  420. FEDERICO A, Tinazzi M, Tamburin S
    MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27329.
    PubMed    


  421. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect.
    Mov Disord. 2018 Feb 20. doi: 10.1002/mds.27339.
    PubMed    


  422. WYMAN-CHICK KA, Martin PK, Weintraub D, Sperling SA, et al
    Selection of normative group affects rates of mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27335.
    PubMed     Abstract available


  423. PARK JS, Koentjoro B, Klein C, Sue CM, et al
    Single heterozygous ATP13A2 mutations cause cellular dysfunction associated with Parkinson's disease.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27327.
    PubMed    


  424. SAMOTUS O, Parrent A, Jog M
    Spinal cord stimulation therapy for gait dysfunction in advanced Parkinson's disease patients.
    Mov Disord. 2018 Feb 14. doi: 10.1002/mds.27299.
    PubMed     Abstract available


  425. FAZIO P, Svenningsson P, Cselenyi Z, Halldin C, et al
    Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27316.
    PubMed     Abstract available


  426. BOUCA-MACHADO R, Lennaerts-Kats H, Bloem B, Ferreira JJ, et al
    Why palliative care applies to Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27309.
    PubMed    


  427. DAGAN M, Herman T, Harrison R, Zhou J, et al
    Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27300.
    PubMed     Abstract available


  428. PALMA JA
    Autonomic dysfunction in Parkinson's disease and other synucleinopathies: Introduction to the series.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27347.
    PubMed    


  429. ABBASI N, Mohajer B, Abbasi S, Hasanabadi P, et al
    Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27284.
    PubMed     Abstract available


  430. MULAK A
    A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27304.
    PubMed    


  431. MAHLKNECHT P, Gasperi A, Djamshidian A, Kiechl S, et al
    Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study.
    Mov Disord. 2018 Feb 13. doi: 10.1002/mds.27281.
    PubMed     Abstract available


  432. BAHIRAEE A, Ebrahimi R
    A noble pathological role for alpha-synuclein in triggering neurodegeneration of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27306.
    PubMed    


  433. CREED RB, Goldberg MS
    New developments in genetic rat models of Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27296.
    PubMed     Abstract available


  434. WEINTRAUB D, Hamilton JL, Eberling J, Litvan I, et al
    At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2018 Feb 8. doi: 10.1002/mds.27310.
    PubMed    


  435. LAGRAVINESE G, Pelosin E, Bonassi G, Carbone F, et al
    Gait initiation is influenced by emotion processing in Parkinson's disease patients with freezing.
    Mov Disord. 2018 Feb 2. doi: 10.1002/mds.27312.
    PubMed     Abstract available


  436. NAROS G, Grimm F, Weiss D, Gharabaghi A, et al
    Directional communication during movement execution interferes with tremor in Parkinson's disease.
    Mov Disord. 2018;33:251-261.
    PubMed     Abstract available


    January 2018
  437. NOYCE AJ, Dickson J, Rees RN, Bestwick JP, et al
    Dopamine reuptake transporter-single-photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27282.
    PubMed     Abstract available


  438. MOREAU C, Duce JA, Rascol O, Devedjian JC, et al
    Iron as a therapeutic target for Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27275.
    PubMed    


  439. PAL G, Ouyang B, Verhagen L, Serrano G, et al
    Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.
    Mov Disord. 2018 Jan 30. doi: 10.1002/mds.27280.
    PubMed    


  440. CHEN V, Saez-Atienzar S
    A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27248.
    PubMed    


  441. SAVICA R, Grossardt BR, Rocca WA, Bower JH, et al
    Parkinson disease with and without Dementia: A prevalence study and future projections.
    Mov Disord. 2018 Jan 22. doi: 10.1002/mds.27277.
    PubMed     Abstract available


  442. HIMMELBERG MM, West RJH, Wade AR, Elliott CJH, et al
    A perceptive plus in Parkinson's disease.
    Mov Disord. 2018 Jan 14. doi: 10.1002/mds.27240.
    PubMed    


  443. KIM IY, O'Reilly EJ, Hughes KC, Gao X, et al
    Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk.
    Mov Disord. 2018 Jan 10. doi: 10.1002/mds.27279.
    PubMed     Abstract available


  444. GARCIA-SANZ P, Moratalla R
    The importance of cholesterol in Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27251.
    PubMed    


  445. GAO Y, Wilson GR, Stephenson SEM, Bozaoglu K, et al
    The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease.
    Mov Disord. 2018 Jan 9. doi: 10.1002/mds.27270.
    PubMed     Abstract available


  446. AHMADI NS
    Mutant parkin-induced parkinsonism from an electrical point of view: Abnormal excitatory response to dopamine resolved after substitution.
    Mov Disord. 2018;33:71.
    PubMed    


  447. FASANO A, Lang AE, Espay AJ
    What is "essential" about essential tremor? A diagnostic placeholder.
    Mov Disord. 2018;33:58-61.
    PubMed    


  448. ALBANESE A
    Classifying tremor: Language matters.
    Mov Disord. 2018;33:3-4.
    PubMed    


  449. SCHEPERJANS F
    The prodromal microbiome.
    Mov Disord. 2018;33:5-7.
    PubMed    


    December 2017
  450. MEROLA A, Romagnolo A, Rosso M, Suri R, et al
    Autonomic dysfunction in Parkinson's disease: A prospective cohort study.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27268.
    PubMed     Abstract available


  451. MARRINAN SL, Otiker T, Vasist LS, Gibson RA, et al
    A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27259.
    PubMed     Abstract available


  452. BOWER JH, Grossardt BR, Rocca WA, Savica R, et al
    Prevalence of and indications for antipsychotic use in Parkinson's disease.
    Mov Disord. 2017 Dec 26. doi: 10.1002/mds.27256.
    PubMed     Abstract available


  453. LIU Z, Tang B
    Novel Parkinson's disease risk loci identified through a meta-analysis of genome-wide association studies.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27276.
    PubMed    


  454. BOUTHOUR W, Wegrzyk J, Momjian S, Peron J, et al
    Short pulse width in subthalamic stimulation in Parkinson's disease: a randomized, double-blind study.
    Mov Disord. 2017 Dec 21. doi: 10.1002/mds.27265.
    PubMed     Abstract available


  455. ROOSEN DA, Singleton AB
    Leucine rich repeat kinase knockout (LRRK KO) mouse model: Linking pathological hallmarks of inherited and sporadic Parkinson's disease.
    Mov Disord. 2017 Dec 19. doi: 10.1002/mds.27267.
    PubMed    


  456. PICCONI B, Hernandez LF, Obeso JA, Calabresi P, et al
    Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias.
    Mov Disord. 2017 Dec 8. doi: 10.1002/mds.27261.
    PubMed     Abstract available


  457. GOLDMAN JG, Andrews H, Amara A, Naito A, et al
    Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27232.
    PubMed     Abstract available


  458. KIEBURTZ K, Katz R, Olanow CW
    New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27220.
    PubMed    


  459. FERNANDES HJR
    Beyond the lysosome: Cholesterol role on endoplasmic reticulum and lipid droplets in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27249.
    PubMed    


  460. PADMANABHAN S, Burke RE
    Induction of axon growth in the adult brain: A new approach to restoration in Parkinson's disease.
    Mov Disord. 2017 Dec 4. doi: 10.1002/mds.27209.
    PubMed    


    November 2017
  461. LOZANO CS, Tam J, Lozano AM
    The changing landscape of surgery for Parkinson's Disease.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27228.
    PubMed     Abstract available


  462. BHATIA KP, Bain P, Bajaj N, Elble RJ, et al
    Consensus Statement on the classification of tremors, from the task force on tremor of the International Parkinson and Movement Disorder Society.
    Mov Disord. 2017 Nov 30. doi: 10.1002/mds.27121.
    PubMed     Abstract available


  463. SVENSSON E, Henderson VW, Szepligeti S, Stokholm MG, et al
    Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study.
    Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27253.
    PubMed     Abstract available


  464. BUARD I, Sciacca DM, Martin CS, Rogers S, et al
    Transcranial magnetic stimulation does not improve mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Nov 27. doi: 10.1002/mds.27246.
    PubMed    


  465. TROPEA TF, Xie SX, Rick J, Chahine LM, et al
    APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27204.
    PubMed     Abstract available


  466. KOHSAKA M, Oeda T, Umemura A, Tomita S, et al
    Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27243.
    PubMed    


  467. SKORVANEK M, Goldman JG, Jahanshahi M, Marras C, et al
    Global scales for cognitive screening in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27233.
    PubMed     Abstract available


  468. KULIKOVSKAJA L, Seibler P
    Dopamine oxidation mediates a time-dependent pathological cascade in Parkinson's disease.
    Mov Disord. 2017 Nov 23. doi: 10.1002/mds.27262.
    PubMed    


  469. STEIGERWALD F, Timmermann L, Kuhn A, Schnitzler A, et al
    Pulse duration settings in subthalamic stimulation for Parkinson's disease.
    Mov Disord. 2017 Nov 22. doi: 10.1002/mds.27238.
    PubMed     Abstract available


  470. POCHARD C, Leclair-Visonneau L, Coron E, Neunlist M, et al
    Cyclooxygenase 2 is upregulated in the gastrointestinal tract in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27237.
    PubMed    


  471. WEAVER FM, Stroupe KT, Smith B, Gonzalez B, et al
    Survival in patients with Parkinson's disease after deep brain stimulation or medical management.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27235.
    PubMed     Abstract available


  472. DAFSARI HS, Reker P, Stalinski L, Silverdale M, et al
    Quality of life outcomes after subthalamic stimulation in Parkinson's disease depends on age.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27222.
    PubMed     Abstract available


  473. SYRKIN-NIKOLAU J, Neuville R, O'Day J, Anidi C, et al
    Coordinated reset vibrotactile stimulation shows prolonged improvement in Parkinson's disease.
    Mov Disord. 2017 Nov 18. doi: 10.1002/mds.27223.
    PubMed    


  474. ELAHI E
    PTRHD1 and possibly ADORA1 mutations contribute to Parkinsonism with intellectual disability.
    Mov Disord. 2017 Nov 16. doi: 10.1002/mds.27126.
    PubMed    


  475. HELMICH RC
    The cerebral basis of Parkinsonian tremor: A network perspective.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27224.
    PubMed     Abstract available


  476. GOETZ CG
    Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years?
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27214.
    PubMed    


  477. ARNALDI D, De Carli F, Fama F, Brugnolo A, et al
    Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers.
    Mov Disord. 2017 Nov 9. doi: 10.1002/mds.27190.
    PubMed     Abstract available


  478. SCHNEIDER SA, Alcalay RN
    Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.
    Mov Disord. 2017;32:1504-1523.
    PubMed     Abstract available


  479. SCHAPIRA AH
    What would James Parkinson think? A virtual dialogue on factors influencing the development of Parkinson's disease.
    Mov Disord. 2017;32:1499-1500.
    PubMed    


    October 2017
  480. SOHAIL S, Yu L, Schneider JA, Bennett DA, et al
    Sleep fragmentation and Parkinson's disease pathology in older adults without Parkinson's disease.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27200.
    PubMed     Abstract available


  481. LI W, Lao-Kaim NP, Roussakis AA, Martin-Bastida A, et al
    11 C-PE2I and 18 F-Dopa PET for assessing progression rate in Parkinson's: A longitudinal study.
    Mov Disord. 2017 Oct 30. doi: 10.1002/mds.27183.
    PubMed     Abstract available


  482. METEREAU E, Beaudoin-Gobert M, Duperrier S, Thobois S, et al
    Diffusion tensor imaging marks dopaminergic and serotonergic lesions in the Parkinsonian monkey.
    Mov Disord. 2017 Oct 27. doi: 10.1002/mds.27201.
    PubMed     Abstract available


  483. FASANO A, Canning CG, Hausdorff JM, Lord S, et al
    Falls in Parkinson's disease: A complex and evolving picture.
    Mov Disord. 2017 Oct 25. doi: 10.1002/mds.27195.
    PubMed     Abstract available


  484. WEINTRAUB D, Chahine LM, Hawkins KA, Siderowf A, et al
    Cognition and the course of prodromal Parkinson's disease.
    Mov Disord. 2017 Oct 24. doi: 10.1002/mds.27189.
    PubMed     Abstract available


  485. FENGLER S, Liepelt-Scarfone I, Brockmann K, Schaffer E, et al
    Cognitive changes in prodromal Parkinson's disease: A review.
    Mov Disord. 2017 Oct 5. doi: 10.1002/mds.27135.
    PubMed     Abstract available


  486. ASCHERIO A, Schwarzschild MA
    Dietary antioxidants and Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27194.
    PubMed    


  487. SAEED U, Masellis M
    Unraveling PINK1 regulation: Ubiquitination of its mature form and insights for Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27171.
    PubMed    


  488. MACLEOD AD, Dalen I, Tysnes OB, Larsen JP, et al
    Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27177.
    PubMed     Abstract available


  489. WEIL RS, Pappa K, Schade RN, Schrag AE, et al
    The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27176.
    PubMed    


  490. FORD KJ, Joop A, Memon RA, Wood KH, et al
    Pedestrian safety in patients with Parkinson's disease: A case-control study.
    Mov Disord. 2017 Oct 4. doi: 10.1002/mds.27124.
    PubMed     Abstract available


  491. STANDAERT DG
    What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease.
    Mov Disord. 2017;32:1341-1342.
    PubMed    


    September 2017
  492. THEVATHASAN W, Debu B, Aziz T, Bloem BR, et al
    Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review.
    Mov Disord. 2017 Sep 28. doi: 10.1002/mds.27098.
    PubMed     Abstract available


  493. BIUNDO R, Weis L, Abbruzzese G, Calandra-Buonaura G, et al
    Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study.
    Mov Disord. 2017 Sep 27. doi: 10.1002/mds.27181.
    PubMed     Abstract available


  494. TESSITORE A, De Micco R, Giordano A, di Nardo F, et al
    Intrinsic brain connectivity predicts impulse control disorders in patients with Parkinson's disease.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27139.
    PubMed     Abstract available


  495. ROSE SJ, Harrast P, Donsante C, Fan X, et al
    Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
    Mov Disord. 2017 Sep 26. doi: 10.1002/mds.27169.
    PubMed     Abstract available


  496. FULLARD ME, Xie SX, Marek K, Stern M, et al
    Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.
    Mov Disord. 2017 Sep 14. doi: 10.1002/mds.27127.
    PubMed     Abstract available


  497. SAME K, Ghazi Sherbaf F, Aarabi MH
    New link between Parkinson's and Alzheimer's: Research uncovers the role of mutant leucine rich repeat kinase 2 and amyloid precursor protein.
    Mov Disord. 2017 Sep 13. doi: 10.1002/mds.27170.
    PubMed    


  498. FRISALDI E, Carlino E, Zibetti M, Barbiani D, et al
    The placebo effect on bradykinesia in Parkinson's disease with and without prior drug conditioning.
    Mov Disord. 2017 Sep 12. doi: 10.1002/mds.27142.
    PubMed     Abstract available


  499. YANG F, Wolk A, Hakansson N, Pedersen NL, et al
    Dietary antioxidants and risk of Parkinson's disease in two population-based cohorts.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27120.
    PubMed     Abstract available


  500. HAN W, Sapkota S, Camicioli R, Dixon RA, et al
    Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27173.
    PubMed     Abstract available


  501. GHAHREMANI A, Chen R
    Deep brain stimulation modulates the shape of cortical beta oscillations in Parkinson's disease.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27144.
    PubMed    


  502. EUSEBI P, Giannandrea D, Biscetti L, Abraha I, et al
    Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2017 Sep 7. doi: 10.1002/mds.27110.
    PubMed     Abstract available


  503. BRAKEDAL B, Flones I, Reiter SF, Torkildsen O, et al
    Glitazone use associated with reduced risk of Parkinson's disease.
    Mov Disord. 2017 Sep 1. doi: 10.1002/mds.27128.
    PubMed     Abstract available


  504. OBESO JA, Stamelou M, Goetz CG, Poewe W, et al
    Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.
    Mov Disord. 2017;32:1264-1310.
    PubMed     Abstract available



  505. Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative
    Mov Disord. 2017;32:e1-e19.
    PubMed    


    August 2017
  506. TREZZI JP, Galozzi S, Jaeger C, Barkovits K, et al
    Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27132.
    PubMed     Abstract available


  507. HEINTZ-BUSCHART A, Pandey U, Wicke T, Sixel-Doring F, et al
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27105.
    PubMed     Abstract available


  508. TURCANO P, Mielke MM, Josephs KA, Bower JH, et al
    Clinicopathologic discrepancies in a population-based incidence study of parkinsonism in olmsted county: 1991-2010.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27125.
    PubMed     Abstract available


  509. PARNETTI L, Paciotti S, Eusebi P, Dardis A, et al
    Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27136.
    PubMed     Abstract available


  510. BORGHAMMER P
    How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology.
    Mov Disord. 2017 Aug 26. doi: 10.1002/mds.27138.
    PubMed     Abstract available


  511. OERTEL W, Eggert K, Pahwa R, Tanner CM, et al
    Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Mov Disord. 2017 Aug 21. doi: 10.1002/mds.27131.
    PubMed     Abstract available


  512. CHAUDHURI KR, Jenner P
    Two hundred years since James Parkinson's essay on the shaking palsy-Have we made progress? Insights from the James Parkinson's 200 years course held in London, March 2017.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27104.
    PubMed    


  513. POLLARD EE
    Where we've gone "right" in the Parkinson's community.
    Mov Disord. 2017 Aug 11. doi: 10.1002/mds.27076.
    PubMed    


  514. ROCCA WA
    The future burden of Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27114.
    PubMed    


  515. MIYAUE N, Tada S, Ando R, Yabe H, et al
    cascade stomach associated with delayed-on or no-on phenomenon in a patient with Parkinson's disease.
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27109.
    PubMed    


  516. BANDRES-CIGA S, Cookson MR
    Alpha-synuclein triggers T-cell response. Is Parkinson's disease an autoimmune disorder?
    Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27116.
    PubMed    


  517. GARCIA-SANZ P, Orgaz L, Bueno-Gil G, Espadas I, et al
    N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.
    Mov Disord. 2017 Aug 5. doi: 10.1002/mds.27119.
    PubMed     Abstract available


  518. LILL CM, Klein C
    What would Dr. James Parkinson think today? The role of genetics in Parkinson's disease.
    Mov Disord. 2017;32:1115-1116.
    PubMed    


    July 2017
  519. CHUNG SJ, Shin JH, Cho KH, Lee Y, et al
    Subcortical shape analysis of progressive mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27106.
    PubMed     Abstract available


  520. DELPONT B, Lhommee E, Klinger H, Schmitt E, et al
    Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease.
    Mov Disord. 2017 Jul 24. doi: 10.1002/mds.27101.
    PubMed     Abstract available


  521. OFORI E, Krismer F, Burciu RG, Pasternak O, et al
    Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Mov Disord. 2017 Jul 17. doi: 10.1002/mds.27100.
    PubMed     Abstract available


  522. THIBAULT L, Rascol O, Corvol JC, Ferreira J, et al
    New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.
    Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055.
    PubMed    


  523. PAYAMI H
    The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27099.
    PubMed     Abstract available


  524. KOJOVIC M, Kassavetis P, Parees I, Georgiev D, et al
    Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27091.
    PubMed    


  525. CORREIA GUEDES L, Reimao S, Paulino P, Nunes RG, et al
    Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease.
    Mov Disord. 2017 Jul 7. doi: 10.1002/mds.27083.
    PubMed    


  526. HEINZEL S, Bernhard FP, Roeben B, Nussbaum S, et al
    Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27062.
    PubMed    


  527. SAEZ-ATIENZAR S, Singleton AB
    Parkinson Disease and Clathrin Coat Dynamics at Synapses, Why Not?
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27097.
    PubMed    


  528. SONG N, Wang W, Jia F, Du X, et al
    Assessments of plasma ghrelin levels in the early stages of parkinson's disease.
    Mov Disord. 2017 Jul 6. doi: 10.1002/mds.27095.
    PubMed     Abstract available


  529. HUANG P, Tan YY, Liu DQ, Herzallah MM, et al
    Motor-symptom laterality affects acquisition in Parkinson's disease: A cognitive and functional magnetic resonance imaging study.
    Mov Disord. 2017;32:1047-1055.
    PubMed     Abstract available


  530. OBESO JA, Trenkwalder C
    What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society.
    Mov Disord. 2017;32:951-954.
    PubMed    


    June 2017
  531. ZABETIAN CP, Mata IF
    LARGE-PD: Examining the genetics of Parkinson's disease in Latin America.
    Mov Disord. 2017 Jun 28. doi: 10.1002/mds.27081.
    PubMed    


  532. GOETZ CG, Stebbins GT, Chung KA, Nicholas AP, et al
    Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
    Mov Disord. 2017 Jun 24. doi: 10.1002/mds.27092.
    PubMed    


  533. LHOMMEE E, Boyer F, Wack M, Pelissier P, et al
    Personality, dopamine, and Parkinson's disease: Insights from subthalamic stimulation.
    Mov Disord. 2017 Jun 23. doi: 10.1002/mds.27065.
    PubMed     Abstract available


  534. STEINER LA, Neumann WJ, Staub-Bartelt F, Herz DM, et al
    Subthalamic beta dynamics mirror Parkinsonian bradykinesia months after neurostimulator implantation.
    Mov Disord. 2017 Jun 22. doi: 10.1002/mds.27068.
    PubMed     Abstract available


  535. CHOTIBUT T, Meadows S, Kasanga EA, McInnis T, et al
    Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27077.
    PubMed     Abstract available


  536. BONET-PONCE L, Singleton AB
    Make dopamine neurons great again: An exciting new therapeutic option in parkinson's disease.
    Mov Disord. 2017 Jun 20. doi: 10.1002/mds.27078.
    PubMed    


  537. CLAASSEN DO, Stark AJ, Spears CA, Petersen KJ, et al
    Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors.
    Mov Disord. 2017 Jun 19. doi: 10.1002/mds.27047.
    PubMed     Abstract available


  538. PELOSI A
    Cell-specific alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.
    Mov Disord. 2017 Jun 16. doi: 10.1002/mds.27071.
    PubMed    


  539. FRIEDMAN JH
    Drug-induced parkinsonism.
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27050.
    PubMed    


  540. ROCCA WA, Savica R, Grossardt BR
    Response to Letter by Friedman on "Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study".
    Mov Disord. 2017 Jun 14. doi: 10.1002/mds.27051.
    PubMed    


  541. HOOGLAND J, Boel JA, de Bie RMA, Geskus RB, et al
    Mild cognitive impairment as a risk factor for Parkinson's disease dementia.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27002.
    PubMed     Abstract available


  542. TITOVA N, Chaudhuri KR
    Personalized medicine in Parkinson's disease: Time to be precise.
    Mov Disord. 2017 Jun 12. doi: 10.1002/mds.27027.
    PubMed    


  543. LARSSON SC, Singleton AB, Nalls MA, Richards JB, et al
    No clear support for a role for vitamin D in Parkinson's disease: A Mendelian randomization study.
    Mov Disord. 2017 Jun 8. doi: 10.1002/mds.27069.
    PubMed     Abstract available


  544. ROSSI A, Berger K, Chen H, Leslie D, et al
    Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27063.
    PubMed     Abstract available


  545. KASSUBEK J, Huppertz HJ, Hoglinger GU
    Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27057.
    PubMed    


  546. KUMAR A
    Reprogramming the striatal stars: A new treatment option for Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27067.
    PubMed    


  547. QUATTRONE A, Nigro S
    MRI measures of brainstem in Parkinsonian syndromes: Where we stand and where we need to go.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27056.
    PubMed    


  548. MAHLKNECHT P, Akram H, Georgiev D, Tripoliti E, et al
    Pyramidal tract activation due to subthalamic deep brain stimulation in Parkinson's disease.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.27042.
    PubMed     Abstract available


  549. PINA-FUENTES D, Little S, Oterdoom M, Neal S, et al
    Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principle.
    Mov Disord. 2017 Jun 7. doi: 10.1002/mds.26959.
    PubMed    



  550. Abstracts of the 21st International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2017;32 Suppl 2:S1-S1079.
    PubMed    


  551. MANDEMAKERS W, Quadri M, Stamelou M, Bonifati V, et al
    TMEM230: How does it fit in the etiology and pathogenesis of Parkinson's disease?
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27061.
    PubMed     Abstract available


  552. PEREZ-SORIANO A, Arena JE, Dinelle K, Miao Q, et al
    PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins.
    Mov Disord. 2017 Jun 1. doi: 10.1002/mds.27029.
    PubMed     Abstract available


  553. AKRAM H, Wu C, Hyam J, Foltynie T, et al
    l-Dopa responsiveness is associated with distinctive connectivity patterns in advanced Parkinson's disease.
    Mov Disord. 2017;32:874-883.
    PubMed     Abstract available


  554. VAILLANCOURT DE
    What Would Dr. James Parkinson Think Today? Tau and Other Imaging Possibilities in Parkinson's Disease.
    Mov Disord. 2017;32:805-806.
    PubMed    


  555. LENKA A, Pal PK
    "Miro" in Parkinson's disease: Here, there, everywhere!
    Mov Disord. 2017;32:839.
    PubMed    


    May 2017
  556. NG ASL, Tan EK
    Linking statins and lipids in Parkinson's disease.
    Mov Disord. 2017 May 27. doi: 10.1002/mds.27053.
    PubMed    


  557. DELGADO-ALVARADO M, Gago B, Gorostidi A, Jimenez-Urbieta H, et al
    Tau/alpha-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27001.
    PubMed     Abstract available


  558. KIM YJ, Jeon J, Shin J, Kim NY, et al
    Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease.
    Mov Disord. 2017 May 26. doi: 10.1002/mds.27019.
    PubMed     Abstract available


  559. COLLIER TJ, Kanaan NM, Kordower JH
    Aging and Parkinson's disease: Different sides of the same coin?
    Mov Disord. 2017 May 18. doi: 10.1002/mds.27037.
    PubMed     Abstract available


  560. PILOTTO A, Heinzel S, Suenkel U, Lerche S, et al
    Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.
    Mov Disord. 2017 May 16. doi: 10.1002/mds.27035.
    PubMed     Abstract available


  561. SHAHMOON S, Jahanshahi M
    Optimizing psychosocial adjustment after deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Mov Disord. 2017 May 15. doi: 10.1002/mds.27032.
    PubMed    


  562. YADAV AP, Nicolelis MAL
    Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease.
    Mov Disord. 2017 May 12. doi: 10.1002/mds.27033.
    PubMed     Abstract available


  563. MEROLA A, Rosso M, Romagnolo A, Comi C, et al
    Peripheral neuropathy as marker of severe Parkinson's disease phenotype.
    Mov Disord. 2017 May 8. doi: 10.1002/mds.27025.
    PubMed    


  564. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the International Parkinson and Movement Disorder Society task force.
    Mov Disord. 2017;32:724-725.
    PubMed    


  565. POSTUMA RB
    Sleep Disorders and RBD: What Would James Parkinson Think?
    Mov Disord. 2017;32:705-707.
    PubMed    


  566. ST LOUIS EK, Boeve AR, Boeve BF
    REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    Mov Disord. 2017;32:645-658.
    PubMed     Abstract available


  567. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.
    Mov Disord. 2017;32:722-723.
    PubMed    


  568. MCKENNA D, Peever J
    Degeneration of rapid eye movement sleep circuitry underlies rapid eye movement sleep behavior disorder.
    Mov Disord. 2017;32:636-644.
    PubMed     Abstract available


  569. HOGL B, Stefani A
    Restless legs syndrome and periodic leg movements in patients with movement disorders: Specific considerations.
    Mov Disord. 2017;32:669-681.
    PubMed     Abstract available


    April 2017
  570. STROUWEN C, Molenaar EALM, Munks L, Keus SHJ, et al
    Training dual tasks together or apart in Parkinson's disease: Results from the DUALITY trial.
    Mov Disord. 2017 Apr 25. doi: 10.1002/mds.27014.
    PubMed     Abstract available


  571. DIEZ H, Cortes-Saladelafont E, Ormazabal A, Marmiese AF, et al
    Severe infantile parkinsonism because of a de novo mutation on DLP1 mitochondrial-peroxisomal protein.
    Mov Disord. 2017 Apr 24. doi: 10.1002/mds.27021.
    PubMed    


  572. OLSZEWSKA DA, Lynch T
    Nature's Parkin experiment: Nix-a novel protective mechanism in Parkinson's disease.
    Mov Disord. 2017 Apr 22. doi: 10.1002/mds.27015.
    PubMed    


  573. BEAULIEU ML, Muller MLTM, Bohnen NI
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26994.
    PubMed    


  574. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Have we been overestimating fall rates in Parkinson's disease?
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.27009.
    PubMed    


  575. FERESHTEHNEJAD SM, Montplaisir JY, Pelletier A, Gagnon JF, et al
    Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort.
    Mov Disord. 2017 Apr 21. doi: 10.1002/mds.26989.
    PubMed     Abstract available


  576. BURTE F, Houghton D, Lowes H, Pyle A, et al
    metabolic profiling of Parkinson's disease and mild cognitive impairment.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26992.
    PubMed     Abstract available


  577. KOOLE M, Laere KV, Ahmad R, Ceccarini J, et al
    Brain PET imaging of phosphodiesterase 10A in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.27005.
    PubMed    


  578. CACACE F, Mineo D, Viscomi MT, Latagliata EC, et al
    Intermittent theta-burst stimulation rescues dopamine-dependent corticostriatal synaptic plasticity and motor behavior in experimental parkinsonism: Possible role of glial activity.
    Mov Disord. 2017 Apr 10. doi: 10.1002/mds.26982.
    PubMed     Abstract available


  579. YANG X, An R, Xi J, Zheng J, et al
    Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26996.
    PubMed    


  580. OLANOW CW, Kieburtz K, Leinonen M, Elmer L, et al
    A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.26941.
    PubMed     Abstract available


  581. LIU G, Sterling NW, Kong L, Lewis MM, et al
    Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.
    Mov Disord. 2017 Apr 3. doi: 10.1002/mds.27006.
    PubMed     Abstract available


  582. KORDOWER JH
    What would Dr. James Parkinson think today? parcelling out the circuitry of levodopa-induced dyskinesias.
    Mov Disord. 2017;32:483-484.
    PubMed    


  583. BALCK A, Klein C
    Reduced penetrance of Leucine-rich repeat kinase 2 mutations: Discovering genetic factors of endogenous disease protection.
    Mov Disord. 2017;32:527.
    PubMed    


    March 2017
  584. ORGAZ L, Gil GB
    Modulating mitochondrial pyruvate carrier: A promising therapeutic target in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26962.
    PubMed    


  585. FOX SH, Metman LV, Nutt JG, Brodsky M, et al
    Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976.
    PubMed     Abstract available


  586. PONT-SUNYER C, Tolosa E, Caspell-Garcia C, Coffey C, et al
    The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26964.
    PubMed     Abstract available


  587. LEHERICY S, Vaillancourt DE, Seppi K, Monchi O, et al
    The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Mov Disord. 2017 Mar 28. doi: 10.1002/mds.26968.
    PubMed     Abstract available


  588. BARICHELLA M, Cereda E, Cassani E, Frazzitta G, et al
    A focus on Rome III criteria for the assessment of constipation in Parkinson's disease.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26974.
    PubMed    


  589. XU T, Wang S, Lalchandani RR, Ding JB, et al
    Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex.
    Mov Disord. 2017 Mar 25. doi: 10.1002/mds.26938.
    PubMed     Abstract available


  590. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed    


  591. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Abstract available


  592. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Abstract available


  593. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed    


  594. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Abstract available


  595. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Abstract available


  596. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Abstract available


  597. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed    


    February 2017
  598. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Abstract available


  599. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Abstract available


  600. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed    


  601. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed    


  602. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Abstract available


  603. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Abstract available


  604. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed    


  605. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Abstract available


  606. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed    


  607. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Abstract available


  608. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Abstract available


  609. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Abstract available


  610. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed    


  611. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed    


  612. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed    



  613. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed    


    January 2017
  614. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed    


  615. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Abstract available


  616. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Abstract available


  617. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed    


  618. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed    


  619. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Abstract available


  620. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed    


  621. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Abstract available


  622. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Abstract available


  623. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Abstract available


  624. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed    


  625. BLUMENFELD Z, Koop MM, Prieto TE, Shreve LA, et al
    Sixty-hertz stimulation improves bradykinesia and amplifies subthalamic low-frequency oscillations.
    Mov Disord. 2017;32:80-88.
    PubMed     Abstract available


  626. CHO H, Choi JY, Hwang MS, Lee SH, et al
    Subcortical (18) F-AV-1451 binding patterns in progressive supranuclear palsy.
    Mov Disord. 2017;32:134-140.
    PubMed     Abstract available


  627. VALSKY D, Marmor-Levin O, Deffains M, Eitan R, et al
    Stop! border ahead: Automatic detection of subthalamic exit during deep brain stimulation surgery.
    Mov Disord. 2017;32:70-79.
    PubMed     Abstract available


    December 2016
  628. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Abstract available


  629. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed    


  630. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed    


  631. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Abstract available


  632. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Abstract available


  633. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Abstract available


  634. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Abstract available


  635. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Abstract available


  636. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Abstract available


  637. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Abstract available


    November 2016
  638. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed    


  639. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Abstract available


  640. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Abstract available


  641. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed    


  642. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed    


  643. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Abstract available


  644. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed    


  645. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Abstract available


  646. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed    


  647. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed    


  648. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Abstract available


  649. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Abstract available


  650. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Abstract available


  651. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed    


  652. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed    


  653. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed    


  654. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed    


    October 2016
  655. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed    


  656. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Abstract available


  657. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Abstract available


  658. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed    


  659. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Abstract available


  660. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed    


  661. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Abstract available


  662. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Abstract available


  663. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed    


  664. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed    


  665. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed    


  666. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Abstract available


    September 2016
  667. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed    


  668. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Abstract available


  669. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Abstract available


  670. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Abstract available


  671. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Abstract available


  672. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed    


  673. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Abstract available


    April 2016
  674. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed    


  675. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Abstract available


  676. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Abstract available


    March 2016
  677. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Abstract available


  678. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Abstract available


  679. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Abstract available


  680. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Abstract available


    February 2016
  681. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed    


  682. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed    


  683. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Abstract available


  684. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Abstract available


  685. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Abstract available


  686. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Abstract available


  687. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Abstract available


  688. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Abstract available


    January 2016
  689. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed    


  690. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: